UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June 30,~~December 31, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____

Commission file number: 333-60608

JANEL CORPORATION

(Exact name of registrant as specified in its charter)

Nevada		86-1005291
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

80 Eighth Avenue
New York, New York		10011
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (212) 373-5895

Former name, former address and former fiscal year, if changed from last report: N/A

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbols(s)		Name of each exchange on which registered
None		None		None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer	☐
Non-accelerated filer ☐	Smaller reporting company	☒
	Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes ☐ No ☒

The number of shares of Common Stock outstanding as of ~~August 4, 2023~~February 2, 2024 was 1,186,354.

PART I - FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

JANEL CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

(Unaudited)

	June 30, 2023			September 30, 2022			December 31, 2023			September 30, 2023
ASSETS
Current Assets:
Cash	$	2,773		$	6,591		$	1,579		$	2,461
Accounts receivable, net of allowance for doubtful accounts		30,454			57,077			25,965			27,518
Inventory, net		5,094			4,802			4,628			4,850
Prepaid expenses and other current assets		4,574			3,423			3,844			4,459
Total current assets		42,895			71,893			36,016			39,288
Property and Equipment, net		4,965			5,044			4,845			4,922
Other Assets:
Intangible assets, net		22,709			22,420			22,145			22,683
Goodwill		20,271			18,622			20,317			20,317
Investment in marketable securities at fair value		1,592			2,371
Investment in Rubicon at fair value								864			1,573
Operating lease right of use asset		6,030			5,660			6,853			7,460
Security deposits and other long-term assets		1,104			522			462			591
Total other assets		51,706			49,595			50,641			52,624
Total assets	$	99,566		$	126,532		$	91,502		$	96,834
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Lines of credit	$	19,294		$	26,396		$	17,002		$	19,709
Accounts payable - trade		28,527			44,960			24,058			25,447
Accrued expenses and other current liabilities		5,664			7,194			5,856			6,337
Dividends payable		1,957			1,745			2,100			2,029
Current portion of earnout		1,209			1,664			740			592
Current portion of long-term debt		715			639			716			715
Current portion of deferred acquisition payments		192			188
Current portion of subordinated promissory note-related party		750			425			1,395			1,988
Current portion of operating lease liabilities		1,942			1,825			1,935			2,020
Total current liabilities		60,250			85,036			53,802			58,837
Other Liabilities:
Long-term debt		6,394			7,519			5,197			5,784
Long-term portion of earnout		1,978			2,916			1,996			1,738
Subordinated promissory notes-related party		4,754			5,382			3,480			3,424
Mandatorily redeemable non-controlling interest		430			430			711			565
Deferred income taxes		2,533			2,541			1,341			1,341
Long-term operating lease liabilities		4,318			4,001			5,221			5,689
Other liabilities		491			380			509			483
Total other liabilities		20,898			23,169			18,455			19,024
Total liabilities		81,148			108,205			72,257			77,861
Stockholders’ Equity:
Preferred Stock, $0.001 par value; 100,000 shares authorized
Series C 30,000 shares authorized and 11,368 shares issued and outstanding at June 30, 2023 and September 30, 2022, liquidation value of $7,641 and $7,429 at June 30, 2023 and September 30, 2022, respectively		—			—
Common stock, $0.001 par value; 4,500,000 shares authorized, 1,206,354 issued and 1,186,354 outstanding as of June 30, 2023 and September 30, 2022, respectively		1			1
Series C; 30,000 shares authorized and 11,368 shares issued and outstanding at December 31, 2023 and September 30, 2023, liquidation value of $7,784 and $7,713 at December 31, 2023 and September 30, 2023, respectively								—			—
Common stock, $0.001 par value; 4,500,000 shares authorized, 1,206,354 issued and 1,186,354 outstanding as of December 31, 2023 and September 30, 2023, respectively								1			1
Paid-in capital		17,127			17,184			17,103			17,107
Common treasury stock, at cost, 20,000 shares		(240	)		(240	)		(240	)		(240	)
Accumulated earnings		1,530			1,382			2,381			2,105
Total stockholders’ equity		18,418			18,327			19,245			18,973
Total liabilities and stockholders’ equity	$	99,566		$	126,532		$	91,502		$	96,834

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

JANEL CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(Unaudited)

	Three Months Ended June 30,						Nine Months Ended June 30,						Three Months Ended December 31,
	2023			2022			2023			2022			2023			2022
Revenue	$	42,557		$	78,984		$	144,979		$	243,149
Forwarding expenses and cost of revenue		28,898			61,819			102,654			193,986
Revenues													$	41,035		$	57,044
Forwarding expenses and cost of revenues														26,890			42,127
Gross profit		13,659			17,165			42,325			49,163			14,145			14,917
Cost and Expenses:
Selling, general and administrative		12,948			13,505			38,261			39,718			12,605			13,011
Amortization of intangible assets		524			489			1,593			1,485			538			526
Total Costs and Expenses		13,472			13,994			39,854			41,203			13,143			13,537
Income from Operations		187			3,171			2,471			7,960			1,002			1,380
Other Items:
Interest expense		(528	)		(299	)		(1,476	)		(847	)		(524	)		(474	)
Unrealized loss on marketable securities		(269	)		—			(779	)		—
(Loss) Income Before Income Taxes		(610	)		2,872			216			7,113
Income tax benefit (expense)		180			(714	)		(68	)		(1,994	)
Net (Loss) Income		(430	)		2,158			148			5,119
Other income (expense)														(10	)		(399	)
Income Before Income Taxes														468			507
Income tax expense														(192	)		(147	)
Net Income														276			360
Preferred stock dividends		(70	)		(71	)		(212	)		(515	)		(72	)		(72	)
Non-controlling interest dividends		—			—			—			(61	)
Net (Loss) Income Available to Common Stockholders	$	(500	)	$	2,087		$	(64	)	$	4,543

Net (loss) income per share
Net Income Available to Common Stockholders													$	204		$	288
Net income per share
Basic	$	(0.36	)	$	2.04		$	0.12		$	5.13		$	$ 0.23		$	$ 0.30
Diluted	$	(0.36	)	$	1.93		$	0.12		$	4.85		$	$ 0.23		$	$ 0.30
Net (loss) income per share attributable to common stockholders:
Net income per share attributable to common stockholders:
Basic	$	(0.42	)	$	1.97		$	(0.05	)	$	4.56		$	$ 0.17		$	$ 0.24
Diluted	$	(0.42	)	$	1.87		$	(0.05	)	$	4.31		$	$ 0.17		$	$ 0.24
Weighted average number of shares outstanding:
Basic		1,186.4			1,057.7			1,186.4			996.9			1,186.3			1,186.3
Diluted		1,186.4			1,116.6			1,186.4			1,055.0			1,202.1			1,208.2

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

JANEL CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

(in thousands, except share and per share data)

(Unaudited)

	PREFERRED STOCK				COMMON STOCK				PAID-IN CAPITAL			COMMON TREASURY STOCK					ACCUMULATED EARNINGS			TOTAL EQUITY			PREFERRED STOCK				COMMON STOCK				PAID-IN CAPITAL			COMMON TREASURY STOCK					ACCUMULATED EARNINGS		TOTAL EQUITY
	SHARES			$	SHARES		$			$		SHARES		$			$			$			SHARES			$	SHARES		$			$		SHARES		$			$			$
Balance - September 30, 2022		11,368	$	—		1,206,354	$	1	$	17,184			20,000	$	(240	)	$	1,382		$	18,327
Balance - September 30, 2023																								11,368	$	—		1,206,354	$	1	$	17,107			20,000	$	(240	)	$	2,105	$	18,973
Net Income		—		—		—		—		—			—		—			360			360			—		—		—		—		—			—		—			276		276
Dividends to preferred stockholders		—		—		—		—		(72	)		—		—			—			(72	)		—		—		—		—		(72	)		—		—			—		(72	)
Stock based compensation		—		—		—		—		51			—		—			—			51			—		—		—		—		68			—		—			—		68
Balance - December 31, 2022		11,368		—		1,206,354		1		17,163			20,000		(240	)		1,742			18,666
Net Income		—		—		—		—		—			—		—			218			218
Dividends to preferred stockholders		—		—		—		—		(70	)		—		—			—			(70	)
Stock based compensation		—		—		—		—		53			—		—			—			53
Balance - March 31, 2023		11,368		—		1,206,354		1		17,146			20,000		(240	)		1,960			18,867
Net (loss)		—		—		—		—		—			—		—			(430	)		(430	)
Dividends to preferred stockholders		—		—		—		—		(70	)		—		—			—			(70	)
Stock based compensation		—		—		—		—		51			—		—			—			51
Balance - June 30, 2023		11,368	$	—		1,206,354	$	1	$	17,127			20,000	$	(240	)	$	1,530		$	18,418
Balance - December 31, 2023																								11,368	$	—		1,206,354	$	1	$	17,103			20,000	$	(240	)	$	2,381	$	19,245

PREFERRED STOCK COMMON STOCK PAID-IN CAPITAL
COMMON TREASURY
STOCK

ACCUMULATED
EARNINGS
(DEFICIT)
TOTAL EQUITY
SHARES
$

SHARES $
$
SHARES
$

$

$

Balance - September 30, 2021 20,991 $
— 962,207 $ 1 $ 14,838 20,000 $ (240 ) $ 3,520 $ 18,119
Net Income — — — — — — — 1,688 1,688
Dividends to preferred stockholders — — — — (211 ) — — — (211 )
Stock based compensation — — — — 29 — — — 29
Stock option exercise — — 17,500 — 85 — — — 85
Balance - December 31, 2021 20,991 — 979,707 1 14,741 20,000 (240 ) 5,208 19,710
Net Income — — — — — — — 1,273 1,273
Dividends to preferred stockholders — — — — (233 ) — — — (233 )
Dividend to non-controlling interest
— — — — (61 ) — — — (61 )
Preferred C shares purchased
(4,687 ) — — — (1,731 ) — — — (1,731 )
Preferred C shares converted
(4,905 ) — 65,205 — — — — — —
Preferred B shares converted
(31 ) — 306 — — — — — —
Stock based compensation — — 15,000 — 718 — — — 718
Stock options exercise
— — 17,500 — 76 — — — 76
Balance - March 31, 2022
11,368
— 1,077,718
1
13,510 20,000
(240 )
6,481
19,752
Net Income
— — — — — — — 2,158 2,158
Dividends to preferred stockholders
—
—
—
—
(71 ) —
—
—
(71 )
Stock based compensation
— — — — 22 — — — 22
Balance - June 30, 2022
11,368 $
— 1,077,718 $
1 $
13,461 20,000 $
(240 ) $
8,639 $
21,861

	PREFERRED STOCK				COMMON STOCK				PAID-IN CAPITAL			COMMON TREASURY STOCK					ACCUMULATED EARNINGS (DEFICIT)		TOTAL EQUITY
	SHARES			$	SHARES		$			$		SHARES		$				$		$
Balance - September 30, 2022		11,368	$	—		1,206,354	$	1	$	17,184			20,000	$	(240	)	$	1,382	$	18,327
Net Income		—		—		—		—		—			—		—			360		360
Dividends to preferred stockholders		—		—		—		—		(72	)		—		—			—		(72	)
Stock based compensation		—		—		—		—		51			—		—			—		51
Balance - December 31, 2022		11,368	$	—		1,206,354	$	1	$	17,163			20,000	$	(240	)	$	1,742	$	18,666

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

JANEL CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

	Nine Months Ended June 30,						Three Months Ended December 31,
	2023			2022			2023			2022
Cash Flows From Operating Activities:
Cash flows from operating activities:
Net income	$	148		$	5,119		$	276		$	360
Adjustments to reconcile net income to net cash provided by operating activities:
(Recovery of) Provision for uncollectible accounts		(292	)		354			(153	)		(71	)
Depreciation		373			351			130			121
Deferred income tax provision		(8	)		(185	)		—			(15	)
Amortization of intangible assets		1,593			1,485			538			526
Amortization of acquired inventory valuation		320			393			83			90
Amortization of loan costs		63			7			26			4
Stock-based compensation		185			800			71			61
Unrealized loss on marketable securities		779			—			709			399
Change in fair value of mandatorily redeemable noncontrolling interest		—			58			146			—
Fair value adjustment of contingent earnout liabilities								405			—
Gain on extinguishment								(21	)		—
Changes in operating assets and liabilities, net of effects of acquisitions:
Accounts receivable		27,056			(10,026	)		1,706			14,656
Inventory		(106	)		(1,299	)		139			84
Prepaid expenses and other current assets		(1,151	)		(724	)		616			623
Security deposits and other long-term assets		(82	)		44			130			31
Accounts payable and accrued expenses		(17,996	)		12,275			(1,876	)		(11,115	)
Other liabilities		174			26			81			26
Net cash provided by operating activities		11,056			8,678			3,006			5,780
Cash Flows From Investing Activities:
Cash flows from investing activities:
Acquisition of property and equipment, net of disposals		(267	)		(477	)		(53	)		(80	)
Earnout payment		(1,693	)		—
Acquisitions		(4,401	)		(112	)		—			(2,847	)
Net cash used in investing activities		(6,361	)		(589	)		(53	)		(2,927	)
Cash Flows From Financing Activities:
Cash flows from financing activities:
Repayments of term loan		(1,113	)		(728	)		(612	)		(347	)
Proceeds from stock option exercise		—			161
Lines of credit payments, net		(7,101	)		(6,717	)		(2,707	)		(5,076	)
Repayment of subordinate promissory notes		(299	)		(142	)
Dividends paid to minority shareholders		—			(61	)
Dividends paid to preferred stockholders		—			(657	)
Repurchase of Series C Preferred Stock		—			(2,343	)
Repayment of subordinate promissory notes, net								(516	)		134
Net cash used in financing activities		(8,513	)		(10,487	)		(3,835	)		(5,289	)
Net (decrease) in cash		(3,818	)		(2,398	)		(882	)		(2,436	)
Cash at beginning of the period		6,591			6,234			2,461			6,591
Cash at end of period	$	2,773		$	3,836		$	1,579		$	4,155

Supplemental Disclosure of Cash Flow Information:
Cash paid during the period for:
Interest	$	1,208		$	597		$	511		$	380
Income taxes	$	1,300		$	1,261		$	156		$	9
Non-cash operating activities:
Contingent earnout acquisition	$	300		$	—		$	—		$	600
Due to former owner	$	455		$	—		$	—		$	455
Non-cash investing activities:
Purchase price adjustments	$	—		$	112
Non-cash financing activities:
Dividends declared to preferred stockholders	$	212		$	515		$	72		$	72

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

JANEL CORPORATION AND SUBSIDIARIES

NOTES ~~NOTES~~ TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (in thousands, except per share data)

1.	BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

The accompanying interim unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of Article 8 of Regulation S-X and the instructions to Form 10-Q of the Securities and Exchange Commission. As a result, certain information and footnote disclosures normally included in audited financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. Janel Corporation (the “Company” or “Janel”) believes that the disclosures made are adequate to make the information presented not misleading. The condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. The results of operations for the periods presented are not necessarily indicative of the results to be expected for a full fiscal year, or any other period. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Form 10-K as filed with the Securities and Exchange Commission.

Business Description

Janel is a holding company with subsidiaries in three business segments: Logistics, Life Sciences and Manufacturing. The Company strives to create shareholder value primarily through three strategic priorities: supporting its businesses’ efforts to make investments and to build long-term profits; allocating Janel’s capital at high risk-adjusted rates of return; and attracting and retaining exceptional talent.

Management at the holding company focuses on significant capital allocation decisions, corporate governance and supporting Janel’s subsidiaries where appropriate. Janel expects to grow through its subsidiaries’ organic growth and by completing acquisitions. We plan to either acquire businesses within our existing segments or expand our portfolio into new strategic segments. Our acquisition strategy focuses on reasonably-priced companies with strong and capable management teams, attractive existing business economics and stable and predictable earnings power.

Revenue and revenue recognition

Logistics

~~Revenue is~~Revenues are recognized upon transfer of control of promised services to customers. With respect to its Logistics segment, the Company has determined that in general each shipment transaction or service order constitutes a separate contract with the customer. When the Company provides multiple services to a customer, different contracts may be present for different services.

The Company typically satisfies its performance obligations as services are rendered at a point in time. A typical shipment would include services rendered at origin, such as pick-up and delivery to port, freight services from origin to destination port and destination services, such as customs clearance and final delivery. The Company measures the performance of its obligations as services are completed at a point in time during the life of a shipment, including services at origin, freight and destination. The Company fulfills nearly all of its performance obligations within a one- to two-month period.

The Company evaluates whether amounts billed to customers should be reported as gross or net ~~revenue.~~revenues. Generally, ~~revenue is~~revenues are recorded on a gross basis when the Company is acting as principal and is primarily responsible for fulfilling the promise to provide the services, when it has discretion in setting the prices for the services to the customers, and the Company has the ability to direct the use of the services provided by the third party. ~~Revenue is~~Revenues are recognized on a net basis when the Company is acting as agent and we do not have latitude in carrier selection or ~~in establishing~~to establish rates with the carrier.

~~Table of Contents~~

In the Logistics segment, the Company disaggregates its ~~revenues~~revenue by its ~~five~~ four primary service categories: ~~Trucking, Ocean,~~trucking, air, ~~Air, Other,~~ocean and ~~Customs Brokerage~~customs brokerage and other. The Company has aggregated customs brokerage and other for the periods ended December 31, 2023 and 2022. A summary of the Company’s revenues disaggregated by major service lines for the three ~~and nine~~ months ended ~~June 30,~~December 31, 2023 and 2022 iswas as follows ~~(in~~(in thousands):

Three Months Ended
June 30,

Nine Months Ended
June 30,

2023

2022

2023

2022

Service Type
Trucking
$ 19,314 $ 24,920 $ 61,671 $ 70,269
Ocean 7,502 28,633 34,908 94,813
Air 5,638 13,716 17,096 41,063
Other 2,906 3,619 8,771 10,546
Customs Brokerage
2,124

2,796

6,716

9,622

Total
$
37,484

$
73,684

$
129,162

$
226,313

	Three Months Ended December 31,
	2023		2022
Service Type
Trucking	$	17,997	$	22,761
Air		6,711		6,239
Ocean		6,448		18,166
Customs brokerage and other		4,059		4,634
Total	$	35,215	$	51,800

The results for the nine months ended June 30, 2022 include an immaterial correction in the classification of service type revenue. The correction resulted in a decrease of the Other category of $1,518 and an increase to Ocean, Air, Trucking and Customs Brokerage of $1,019, $410, $35 and $54, respectively. The corrections had no effect on reported revenue or results of operations.

Table of Contents

Life Sciences and Manufacturing

~~Revenue~~ Revenues from the Company’s Life Sciences segment are derived from the sale of high-quality monoclonal and polyclonal antibodies, diagnostic reagents and diagnostic kits and other immunoreagents for biomedical research and antibody manufacturing. ~~Revenue~~Revenues from the Company’s Manufacturing segment, which is comprised of Indco, a majority-owned subsidiary of the Company that manufactures and distributes mixing equipment and apparatus for specific applications within various industries, ~~(“Indco”),~~ are derived from the engineering, manufacture and delivery of specialty mixing equipment and accessories. ~~Revenue~~Revenues for Life Sciences and Manufacturing are recognized when products are shipped, and risk of loss is transferred to the carrier(s) used.

2.	ACQUISITIONS

Fiscal 2023 Acquisitions

Life Sciences

On November 1, 2022, the Company completed a business combination whereby it acquired all of the outstanding stock of ImmunoBioScience Corporation (“IBS”), for an aggregate purchase price of $3,755, net of $153 cash received. At closing, $3,000 was paid in cash, $250 was due to the former stockholder of IBS as a deferred acquisition payment upon integration, $300 was recorded as a preliminary earnout consideration (not to exceed $750) and $205 was recorded as a preliminary working capital adjustment. The acquisition was funded with cash provided by normal operations, and the results of operations of IBS are included in Janel’s condensed consolidated results of operations since the date of the acquisition. In connection with the combination, the Company recorded an aggregate of $1,468 in goodwill and $1,680 in other identifiable intangibles. Supplemental pro forma information has not been provided as the acquisition did not have a significant impact on Janel’s condensed consolidated results of operations, individually or in aggregate. IBS is a developer and manufacturer of high-quality reagents used by research and diagnostic customers. IBS was founded in 2007 and is headquartered in Mukilteo, Washington. The acquisition of IBS was completed to expand our product offerings in our Life Sciences segment.

On March 2, 2023, the Company completed a business combination whereby it acquired all of the outstanding stock of Stephen Hall PhD, Ltd. (“SH”) for an aggregate purchase price of $600. At closing, $500 was paid in cash and $100 was due to the former stockholder of SH as a deferred acquisition payment upon integration. The acquisition was funded with cash provided by normal operations, and the results of operations of SH are included in Janel’s condensed consolidated results of operations since the date of the acquisition. In connection with the combination, the Company recorded an aggregate of $181 in goodwill and $202 in other identifiable intangibles. Supplemental pro forma information has not been provided as the acquisition did not have a significant impact on Janel’s condensed consolidated results of operations, individually or in aggregate. SH is a developer and manufacturer of antibodies and cell culture media for research and diagnostic uses. SH was founded in 2011 and is headquartered in Lafayette, Indiana. The acquisition of SH was completed to expand our product offerings in our Life Sciences segment.

The Company is still finalizing the valuation of assets acquired and liabilities assumed for both IBS and SH, and, as such, the fair value amounts are preliminary and subject to change. Primary amounts subject to adjustment include, but are limited to, intangible assets, fair value of accounts receivable or a change in the goodwill balance.

On May 22, 2023, the Company acquired all the rights, title and interests to a royalty agreement for certain antibody products for a purchase price of $500. The Company recorded this acquisition as a royalty asset, which is included in ~~security~~intangible assets in the accompanying condensed consolidated balance sheet (reclassed from Security deposits and other long-term assets in the ~~accompanying condensed consolidated balance sheet~~current period) and will be amortized over the estimated life of ten years.

~~Table of Contents~~

~~Fiscal 2022 Acquisitions~~

~~Life Sciences~~

On August 15, 2022, the Company completed a business combination whereby it acquired all of the membership interests of ECM Biosciences LLC (“ECM”) for $850, net of $16 cash received. At closing, the former member of ECM was paid $600 in cash and an additional $250 was due to the former member, which is included in accrued expenses and other current liabilities. In connection with the combination, the Company recorded an aggregate of $24 in goodwill and $222 in other identifiable intangibles. This acquisition was funded with cash provided by normal operations. The results of operations of the acquired businesses are included in Janel’s consolidated results of operations since the date of the acquisition and are included in our Life Sciences segment. The acquisition of ECM was completed to expand our product offerings in our Life Sciences segment. Supplemental pro forma information has not been provided as the acquisition did not have a significant impact on Janel’s consolidated results of operations, individually or in aggregate.

~~Investment in Marketable Securities - Rubicon~~

On August 19, 2022, the Company acquired 1,108,000 shares (the “Acquired Shares”) of the common stock, par value $0.001 per share, of Rubicon Technology, Inc. (“Rubicon”), at a price per share of $20.00, in a cash tender offer made pursuant to the Stock Purchase and Sale Agreement, dated July 1, 2022, between the Company and Rubicon (the “Purchase Agreement”). Pursuant to the terms of the Purchase Agreement, the Acquired Shares represented 44.99% of Rubicon’s issued and outstanding shares of common stock as of August 3, 2022, as reported in Rubicon’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022, filed with the SEC on August 12, 2022. Due to share repurchases effectuated by Rubicon, the Company owned approximately 46.6% of Rubicon's issued and outstanding shares of common stock as of June 30, 2023.

~~Rubicon is an advanced materials provider specializing in monocrystalline sapphire for applications in optical and industrial systems.~~

INVENTORY

Inventories consisted of the following (in thousands):

	June 30, 2023			September 30, 2022			December 31, 2023			September 30, 2023
Finished goods	$	1,978		$	1,823		$	1,953		$	2,095
Work-in-process		1,074			763			922			969
Raw materials		2,084			2,260			1,781			1,811
Gross inventory		5,136			4,846			4,656			4,875
Less – reserve for inventory valuation		(42	)		(44	)		(28	)		(25	)
Inventory net	$	5,094		$	4,802		$	4,628		$	4,850

Table of Contents

4.	INTANGIBLE ASSETS

A summary of intangible assets and the estimated useful lives used in the computation of amortization is as follows (in thousands):

	June 30, 2023			September 30, 2022			Life	December 31, 2023			September 30, 2023			Life
Customer relationships	$	25,238		$	23,625		10-24 Years	$	25,238		$	25,238		10-24 Years
Trademarks/names		4,559			4,539		1-20 Years		4,559			4,559		1-20 Years
Trademarks/names		521			521		Indefinite		521			521		Indefinite
Other		1,429			1,180		2-22 Years		1,929			1,929		2-22 Years
		31,747			29,865
Less: Accumulated Amortization		(9,038	)		(7,445	)
Intangible assets, net	$	22,709		$	22,420
Total intangible assets									32,247			32,247
Less: accumulated amortization									(10,102	)		(9,564	)
Total intangible assets, net								$	22,145		$	22,683

The composition of the intangible assets balance at ~~June 30,~~December 31, 2023 and September 30, ~~2022~~2023 is as follows (in thousands):

	June 30, 2023			September 30, 2022			December 31, 2023			September 30, 2023
Logistics	$	18,174		$	18,174		$	18,174		$	18,174
Life Sciences		5,873			3,991			6,373			6,373
Manufacturing		7,700			7,700			7,700			7,700
		31,747			29,865
Less: Accumulated Amortization		(9,038	)		(7,445	)
Intangible assets, net	$	22,709		$	22,420
Total intangible assets								32,247			32,247
Less: accumulated amortization								(10,102	)		(9,564	)
Total intangible assets, net							$	22,145		$	22,683

Amortization expense for the ~~nine~~three months ended ~~June 30~~December 31, 2023 and 2022 was ~~$1,593~~$538 and ~~$1,485,~~$526, respectively.

~~Table of Contents~~

GOODWILL

The Company’s goodwill carrying amounts relate to acquisitions in the Logistics, Life Sciences and Manufacturing business segments.

The composition of the goodwill balance at ~~June 30,~~December 31, 2023 and September 30, ~~2022~~2023 was as follows (in thousands):

	June 30, 2023		September 30, 2022		December 31, 2023		September 30, 2023
Logistics	$	9,175	$	9,175	$	9,175	$	9,175
Life Sciences		6,050		4,401		6,096		6,096
Manufacturing		5,046		5,046		5,046		5,046
Total	$	20,271	$	18,622	$	20,317	$	20,317

6.	NOTES PAYABLE – BANKS

(A)	Santander Bank Facility

The wholly-owned subsidiaries ~~which~~that comprise the Company’s Logistics segment (collectively, the “Janel Group Borrowers”), with the Company as a guarantor, have a Loan and Security Agreement ~~(the~~(as amended, the “Santander Loan Agreement”) with Santander with respect to a revolving line of credit facility (the “Santander Facility”). ~~The Santander Loan Agreement was amended on March 31, 2022 to provide for, a~~mong other changes, the following: (i) the maximum revolving facility amount available was increased from $30,000 to $31,500 (limited to 85% of the borrowers’ eligible accounts receivable borrowing base and reserves, subject to adjustments set forth in the ~~Santander~~ ~~Loan Agreement); (ii) the LIBOR basis on which interest under the~~ ~~Santander~~ Loan Agreement was calculated under certain circumstances was changed to the Secured Overnight Financing Rate (“SOFR”) and interest on the Santander Facility accrues at an annual rate equal to the one-month SOFR plus 2.75%; (iii) a one-time increase from $1,000 to $3,000 in the amount the Company was permitted to distribute to holders of the Company’s Series C Stock if specified conditions are met; and (iv) the amount of indebtedness of the Company’s Antibodies Incorporated subsidiary which the Company was permitted to guaranty was increased from $2,920 to $5,000.

On July 13, 2022, the Santander Loan Agreement was further amended by a Consent, Waiver and Second Amendment (the “Second Santander Amendment”) to (i) increase the maximum revolving facility amount available to $35,000 (limited to 85% of the Janel Group Borrowers’ eligible accounts receivable borrowing base and reserves, subject to adjustments set forth in the Santander Loan Agreement) and (ii) provide for a new bridge term loan to the Company in the principal amount of up to $12,000 (the “Bridge Facility”) to be funded in connection with the acquisition by the Company of up to 45% of the outstanding shares of Rubicon Technology, Inc. (“Rubicon”), subject to the satisfaction of certain customary limited conditions (the “Rubicon Transaction”). The Bridge Facility was drawn on August 18, 2022 and matured on the earlier to occur of (i) twenty (20) business days following the funding of the Bridge Facility and (ii) the date of funding of the dividend to be paid by Rubicon in connection with the Rubicon Transaction. The Company repaid the Bridge Facility in full on August 30, 2022. The Second Santander Amendment also contained a one-time waiver and consent to (a) the consummation of the Rubicon Transaction, and (b) a dividend of $2,500 to be paid by Janel Group (as defined herein) to the Company.

On January 30, 2023, the Santander Loan Agreement was further amended by the Third Amendment to the Amended and Restated Loan and Security Agreement (the “Third Santander Amendment”). As amended by the terms of the Third Santander Amendment, the percentage of the Borrowers’ eligible accounts receivable used to calculate the borrowing base under the Santander Loan Agreement was increased from 85% to 90% for Domestic Insured Accounts (as defined in the Third Santander Amendment), subject to adjustments set forth in the Santander Loan Agreement.

On April 25, 2023, in connection with an amendment to the Credit Agreement entered into with First Merchants Bank ("(“First ~~Merchant"~~Merchants”) as described further below, we entered into the Fourth Amendment to the Amended and Restated Loan and Security Agreement (the “Fourth Santander Amendment”). The Fourth Santander Amendment (i) included modifications to address the amendments made to the First Merchants Credit Facilities (as defined below) and the consolidation of the debt thereunder and (ii) terminated the subordination agreement relating to the Company’s guarantee of the First ~~Merchant's debt.~~Merchants Credit Facilities (as defined below).

On August 22, 2023, we entered into the Fifth Amendment to the Santander Loan Agreement (the “Fifth Santander Amendment”). The Fifth Santander Amendment permitted the Company, in the ordinary course of business, to guaranty obligations of subsidiaries on an unsecured basis in an aggregate amount not to exceed $4,000 and related modifications to certain negative covenants.

Table of Contents

On December 1, 2023, in connection with an amendment (the “Purchase Agreement Amendment”) to that certain Membership Interest Purchase Agreement dated as of September 21, 2021 (the “Purchase Agreement”) among Janel Group, Inc. (“Janel Group”), a wholly-owned subsidiary of the Company, Expedited Logistics and Freight Services, LLC (“ELFS”) and former shareholders of ELFS (the “ELFS Sellers”), (i) the Janel Group Borrowers and Santander entered into an Acknowledgment and Consent Agreement pursuant to which Santander consented to the Purchase Agreement Amendment and the effect of the modifications thereunder on the Santander Loan Agreement and (ii) the ELFS Sellers and Santander entered into an Acknowledgment and Consent Agreement pursuant to which Santander consented to the Purchase Agreement Amendment and the effect of the modifications thereunder on the Subordination Agreement (as defined in the Santander Loan Agreement) between Santander and the ELFS Sellers.

On December 21, 2023, we entered into the Sixth Amendment to the Amended and Restated Loan and Security Agreement, which modified the reporting due date of the monthly borrowing base calculation from the fifth day to the fifteenth day of each month.

The Santander Loan Agreement matures on September 21, 2026. Interest accrues on the Santander Facility at an annual rate equal to the one-month SOFR plus 2.75%. The Janel Group Borrowers’ obligations under the Santander Facility are secured by all of the assets of the Janel Group Borrowers, while the Santander Loan Agreement contains customary terms and covenants. As a result of its terms, the Santander Facility is classified as a current liability on the consolidated balance sheet.

At ~~June 30,~~December 31, 2023, outstanding borrowings under the Santander Facility were ~~$17,644,~~$16,252, representing ~~51.4%~~46.4% of the $35,000 available subject to limitations thereunder, and interest was accruing at an effective interest rate of ~~7.33%~~7.68%.

~~Table of Contents~~

At September 30, ~~2022,~~2023, outstanding borrowings under the Santander Facility were ~~$26,396,~~$18,759, representing ~~75.4%~~53.6% of the $35,000 available thereunder, and interest was accruing at an effective interest rate of ~~5.79%~~7.60%.

The Company was in compliance with the financial covenants defined in the Santander Loan Agreement at both ~~June 30,~~December 31, 2023 and September 30, ~~2022.~~2023.

(B)	First Merchants Bank Credit Facility

On February 29, 2016, Indco entered into a Credit Agreement ~~(the~~(as amended, the “Prior First Merchants Credit Agreement”) with First ~~Merchants, which was subsequently amended on August 30, 2019 and July 1, 2020.~~

On August 1, 2022, Indco and First Merchant entered into Amendment No. 3 to the Prior Credit Agreement, modifying the terms of Indco’s credit facilities. Under the revised terms, the credit facilities consisted of ~~a $5,500 term loan, a~~ $1,000 (limited to the borrowing base and reserves) revolving loan, and the continuation of a mortgage loan in the original principal amount of $680 (collectively, the “Prior First Merchants Facility”). Interest accrued on the term loan at an annual rate equal to one-month adjusted term SOFR plus either 2.75% (if Indco’s total funded debt to EBITDA ratio was less than 2:1), or 3.5% (if Indco’s total funded debt to EBITDA ratio was greater than or equal to 2:1). Interest accrued on the revolving loan at an annual rate equal to one-month adjusted term SOFR plus 2.75%. Interest accrued on the mortgage loan at an annual rate of 4.19%. Indco’s obligations under the Prior First Merchants Credit Facility were secured by all of Indco’s real property and other assets, and are guaranteed by Janel, and Janel’s guarantee of Indco’s obligations were secured by a pledge of Janel’s Indco shares.Merchants.

On April 25, 2023, Indco and certain other Subsidiaries of the Company that are part of the Life ~~Science~~Sciences and Manufacturing segments (together with Indco, the “Borrowers” and each, a “Borrower”), entered into a Credit Agreement (the ~~“Credit~~“First Merchants Credit Agreement”) with First Merchants. The First Merchants Credit Agreement constitutes an amendment and restatement of the Prior First Merchants Credit Agreement. The credit facilities provided under the First Merchants Credit Agreement (the “First Merchants Credit Facilities”) consist of a $3,000 revolving loan (limited to the borrowing base and reserves), a $5,000 acquisition loan, a $6,905 Term A loan and a $620 Term B loan as a continuation of the mortgage loan under the Prior First Merchants Credit Agreement. Interest accrues on the outstanding revolving loan, Term A loan and acquisition loan at an annual rate equal to one-month adjusted term SOFR plus either (i) 2.75% (if the Borrowers’ total funded debt to EBITDA ratio is less or equal to 1.75:1.00) or (ii) 3.50% (if the Borrowers’ total funded debt to EBITDA ratio is greater than to 1.75:1.00). Interest accrues on the Term B loan at an annual rate of 4.19%. The Borrowers’ obligations under the First Merchants Credit Facilities are secured by all of the Borrowers’ real property and other assets, and are guaranteed by the Company, and the Company’s guarantee of the Borrowers’ obligations is secured by a pledge of the Company’s equity interests in certain of the Borrowers. The revolving loan portion will expire on August 1, 2027, the Term A loan portion will mature on April 25, 2033, and the Term B loan portion will mature on July 1, ~~2025 and the~~2025. The acquisition loan will permit multiple draws until October 25, 2024, at which point the outstanding principal amount will amortize, with all remaining amounts ~~due at maturity~~ of the acquisition loan due at maturity on April 25, ~~2029; each of the foregoing maturities, subject to earlier termination as provided in the Credit Agreement and unless renewed or extended.~~2029.

As of ~~June 30,~~December 31, 2023, there ~~was~~were $500 of outstanding borrowings under the acquisition loan, ~~$1,150~~$250 of outstanding borrowings under the revolving loan, ~~$6,847~~$5,645 of outstanding borrowings under the Term A loan and ~~$616~~$604 of outstanding borrowings under the Term B loan, with interest accruing on the acquisition loan and revolving loan at an effective interest rate of ~~7.94%~~8.22% and on the Term A loan and Term B loan at an effective interest rate of ~~8.41%~~8.22% and 4.19%, respectively.

As of September 30, ~~2022,~~2023, there were no$500 of outstanding borrowings under the acquisition loan, $450 of outstanding borrowings under the revolving loan, ~~under the Prior Credit Agreement, $5,420~~$6,235 of outstanding borrowings under the ~~term~~Term A loan ~~under the Prior Credit Agreement,~~ and ~~$631~~$610 of outstanding borrowings under the ~~mortgage~~Term B loan, ~~under the Prior Credit Agreement~~ with interest accruing on ~~such term~~the acquisition loan and ~~mortgage~~revolving loan at an effective interest rate of ~~6.63%~~8.18% and on the Term A loan and Term B loan at an effective interest rate of 8.18% and 4.19%, respectively.

The Company was in compliance with the financial covenants defined in the First Merchants Credit Agreement at ~~June 30,~~December 31, 2023 and ~~the Prior Credit Agreement at~~ September 30, ~~2022.~~2023.

(in thousands)
June 30,
2023

September 30,
2022

Total Debt $ 7,109 $ 6,051
Less Current Portion
(715
)

(574
)
Long-term Portion
$
6,394

$
5,477

Table of Contents

The table below sets forth the total long-term debt, net of capitalized loan fees of $349 for the First Merchants Credit Agreement (in thousands):

	December 31, 2023			September 30, 2023
Total debt	$	5,913		$	6,499
Less current portion		(716	)		(715	)
Long-term portion	$	5,197		$	5,784

~~(C)~~

~~First Northern Bank of Dixon~~

Antibodies Incorporated (“Antibodies”), a wholly-owned subsidiary of the Company, entered into a Business Loan Agreement (the “First Northern Loan Agreement”) with First Northern Bank of Dixon (“First Northern”) on June 21, 2018, as amended November 2019 and October 2, 2020. The First Northern Loan Agreement provided for a $2,235 term loan (the “First Northern Term Loan”) and a $750 revolving credit facility (the “First Northern Revolving Loan”).

~~Table of Contents~~

Antibodies also entered into two separate business loan agreements with First Northern: a $125 term loan in connection with a potential expansion of solar generation capacity on the Antibodies property (the “First Northern Solar Loan”) and a $60 term loan in connection with a potential expansion of generator capacity on the Antibodies property (the “First Northern Generator Loan”).

On April 25, 2023, each of the First Northern Term Loan, the First Northern Revolving Loan, the First Northern Solar Loan and the First Northern Generator Loan was paid in full with the proceeds provided by the First Merchants Credit Facilities and the First Merchants Loan Agreement. In connection with the repayment, each business loan agreement governing such First Northern loans was terminated and all liens granted to First Northern in connection with the First Northern Loan Agreement and such business loan agreements on any property of Antibodies were released. Antibodies has no further obligations owing to First Northern in connection with the First Northern Loan Agreement and such business loan agreements.

As of September 30, 2022, the total amount outstanding under the First Northern Term Loan was $2,084, of which $2,027 is included in long-term debt and $57 is included in current portion of long-term debt, with interest accruing at an effective interest rate of 4.18%.

As of September 30, 2022, the total amount outstanding under the First Northern Solar Loan was $23, of which $15 is included in long-term debt and $8 is included in current portion of long-term debt, with interest accruing at an effective interest rate of 4.43%.

~~As of September 30, 2022, there were no outstanding borrowings under the First Northern Revolving Loan.~~

7.	SUBORDINATED PROMISSORY NOTES - RELATED PARTY

(A)ICT Subordinated Promissory Note

Aves Labs, Inc., a wholly-owned subsidiary of the Company, is the obligor on a fixed 0.5% subordinated promissory note in the amount of $1,850 (the “ICT Subordinated Promissory Note”) issued to the former owner of ImmunoChemistry Technologies, LLC (“ICT”), in connection with a business combination whereby the Company acquired all of the membership interests of ICT. The ICT Subordinated Promissory Note is payable in sixteen scheduled quarterly installments of principal and interest beginning March 4, 2021, matures on December 4, 2024, and may be prepaid, in whole or in part, without premium or penalty.

The ICT Subordinated Promissory Note is ~~guaranteed by the Company and is secured by the Company’s membership interests in ICT. The ICT Subordinated Promissory Note is~~ subordinate to and junior in right of payment for principal interest premiums and other amounts payable to Santander and First ~~Merchants and the First Northern.~~Merchants.

As of ~~June 30,~~December 31, 2023, the amount outstanding under the ICT Subordinated Promissory Note was ~~$404,~~$221, net of a $28 discount, which is included in the current portion of subordinated promissory notes.

As of September 30, 2023, the amount outstanding under the ICT Subordinated Promissory Note was $312, of which ~~$325~~$288 is included in the current portion of subordinated promissory notes and ~~$79~~$24 is included in the long-term portion of subordinated promissory notes.

~~As of September 30, 2022, the amount outstanding under the ICT~~(B)ELFS Subordinated Promissory ~~Note was $707, of which $425 is included in the current portion of subordinated promissory notes and $282 is included in the long-term portion of subordinated promissory notes.~~Notes

Janel Group~~, Inc. (“Janel Group”), a wholly-owned subsidiary of the Company,~~ is the obligor on four fixed 4% subordinated promissory notes totaling $6,000 in the aggregate (together, the “ELFS Subordinated Promissory Notes”), payable to certain former shareholders of ~~Expedited Logistics and Freight Services, LLC (“ELFS”),~~ELFS, in connection with the Company’s business combination whereby it acquired all the membership interest of ELFS and its related subsidiaries. All of the ELFS Subordinated Promissory Notes are guaranteed by the Company and are subordinate to and junior in right of payment for principal, interest, premiums and other amounts payable to the Santander ~~Bank~~ Facility and the First Merchants ~~Facility.~~Credit Facilities. The ELFS Subordinated Promissory Notes are payable in twelve equal consecutive quarterly installments of principal together with accrued interest. Beginning October 15, 2021 and on the same day of the next eight consecutive calendar quarters, ~~thereafter~~ payment of accrued interest and unpaid interest is due to the former shareholders. Beginning October 15, 2023 and on the same day of the next twelve consecutive calendar quarters, ~~thereafter~~ payment of principal together with accrued interest and unpaid interest is due to the former shareholders. In June 2022, the principal amount of the ELFS Subordinated Promissory Notes was adjusted to $5,100 due to a revised working capital adjustment of $900.

On December 1, 2023, in connection with the Purchase Agreement Amendment described above, the Company extended the ELFS Subordinated Promissory Notes maturity by two years and restored the working capital adjustment (as defined in the Purchase Agreement) by $900, which increased the principal amount of the ELFS Subordinated Promissory Notes to $6,000. The Company evaluated the accounting treatment related to the amendment and determined the agreements are substantially different; accordingly, the Company extinguished the original subordinated promissory notes and recorded the amended ELFS Subordinated Promissory Notes at a fair value of $4,654. As a result, the Company recorded a debt discount of approximately $921 and a $21 gain on extinguishment, which is included in other income expense.

As of December 31, 2023, the gross principal amount outstanding under the ELFS Subordinated Promissory Notes was $5,575 ($4,654 net of a $921 unamortized discount), of which $1,174 was included in the current portion of subordinated promissory notes and $3,480 was included in the long-term portion of subordinated promissory notes.

As of ~~June~~September 30, 2023, the principal amount outstanding under the ELFS Subordinated Promissory Notes was $5,100, of which ~~$425 is~~$1,700 was included in the current portion of subordinated promissory notes and ~~$4,675 was included in the long-term portion of subordinated promissory notes.~~

~~As of September 30, 2022, the amount outstanding under the ELFS Subordinated Promissory Notes was $5,100 and~~ $3,400was included in the long-term portion of subordinated promissory notes.

(in thousands)	June 30, 2023			September 30, 2022			December 31, 2023			September 30, 2023
Total subordinated promissory notes	$	5,504		$	5,807		$	4,875		$	5,412
Less current portion of subordinated promissory notes		(750	)		(425	)		(1,395	)		(1,988	)
Long-term portion of subordinated promissory notes	$	4,754		$	5,382		$	3,480		$	3,424

1211

Table of Contents

8.	STOCKHOLDERS’ EQUITY

(in thousands, except share and per share data)

Preferred Stock

Series C Cumulative Preferred Stock

Shares of the Company’s Series C Cumulative Preferred Stock (the “Series C Stock”) were initially entitled to receive annual dividends at a rate of 7% per annum of the original issuance price of $500, when and if declared by the Company’s ~~Board~~board of ~~Directors,~~directors, with such rate to increase by 2% annually beginning on the third anniversary of issuance of such Series C Stock to a maximum rate of 13%. By the filing of the Certificate of Amendment to the Company’s Certificate of Incorporation on March 31, 2022, the annual dividend rate decreased to 5% per annum of the original issuance price, when and if declared by the Company’s ~~Board~~board of ~~Directors,~~directors, and will increase by 1% beginning on January 1, 2024. Such rate is to increase on each January 1 thereafter for four years to a maximum rate of 9%. The dividend rate of the Series C Stock as of each ~~of June 30,~~December 31, 2023 and September 30, ~~2022~~2023 was 5%.

~~On March 31, 2022, the Company purchased 4,687 shares of the Series C Stock from two holders at a purchase price of $500 per share plus accrued dividends, or an aggregate of $3,000,~~ and exchanged 4,905 shares of Series C Stock plus accrued dividends from one holder, for the issuance of 65,205 shares of the Company’s Common Stock, par value $0.001 per share valued at $47.00 per share of Common Stock (the closing price for the Common Stock on March 30, 2022), or a total value of $3,065. As a result of these transactions, the number of issued and outstanding shares of Series C Stock was reduced from 20,960 shares to 11,368 shares.

9.	STOCK-BASED COMPENSATION

(in thousands, except share and per share data)

On October 30, 2013, the ~~Board~~board of ~~Directors~~directors of the Company adopted the Company’s 2013 Non-Qualified Stock Option Plan (the “2013 Option Plan”) providing for options to purchase up to 100,000 shares of common stock for issuance to directors, officers, employees of and consultants to the Company and its subsidiaries.

On September 21, 2021, the ~~Board~~board of ~~Directors~~directors of the Company adopted the Amended and Restated 2017 Janel Corporation Equity Incentive Plan (the “Amended Plan”) pursuant to which non-statutory stock options, restricted stock awards and stock appreciation rights of the Company’s Common Stock may be granted to employees, directors and consultants to the Company and its subsidiaries. The Amended Plan increased the number of shares of Common Stock that may be issued pursuant to the Amended Plan from 100,000 to 200,000 shares of Common Stock of the Company and was updated to reflect certain other non-substantive amendments.

Total stock-based compensation for the ~~nine~~three months ended ~~June 30,~~December 31, 2023 and 2022 amounted to ~~$185~~$68 and $~~800,~~51, respectively, and is included in selling, general and administrative expense in the Company’s statements of operations.

~~(A)~~

~~Stock Options~~

~~The Company uses the Black-Scholes option pricing model to estimate the fair value of our share-based awards. In applying this model, we use the following assumptions:~~

~~Risk-free interest rate - We determine the risk-free interest rate by using a weighted average assumption equivalent to the expected term based on the U.S. Treasury constant maturity rate.~~

~~Expected term - We estimate the expected term of our options on the average of the vesting date and term of the option.~~

~~Expected volatility - We estimate expected volatility using daily historical trading data of a peer group.~~

•

~~Dividend yield - We have never paid dividends on our common stock and currently have no plans to do so; therefore, no dividend yield is applied.~~

~~Table of Contents~~

~~The fair values of our employee option awards were estimated using the assumptions below, which yielded the following weighted average grant date fair values for the periods presented:~~

	~~Nine Months Ended~~ ~~June 30, 2023~~
~~Risk-free interest rate~~		~~3.98~~	%
~~Expected option term in years~~		~~5.5 - 6.5~~
~~Expected volatility~~		~~93.6~~	%
~~Dividend yield~~		—	%
~~Weighted average grant date fair value~~	$	~~30.06 - $41.24~~

Options ~~for Employees~~

Number
of Options

Weighted
Average
Exercise
Price

Weighted
Average
Remaining
Contractual
Term (in years)

Aggregate
Intrinsic
Value
(in thousands)

Outstanding balance at September 30, 2022
30,993 $ 12.68 6.8 $ 1,251.45
Granted 10,000 $ 53.06 9.5 $ —
Outstanding balance at June 30, 2023

40,993
$ 22.53 6.8 $ 505.73
Exercisable at June 30, 2023

21,831
$ 9.96 5.2 $ 415.77

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding balance at September 30, 2023		40,993		$	22.53		6.6	$	482.49
Granted		12,500		$	28.25		9.8	$	—
Expired		(3,500	)	$	3.25		—	$	—
Outstanding balance at December 31, 2023		49,993		$	25.31		7.6	$	305.63
Exercisable at December 31, 2023		24,162		$	12.63		6.0	$	298.97

The aggregate intrinsic value in the above table was calculated as the difference between the closing price of the Company’s common stock at ~~June 30,~~December 31, 2023 of ~~$29.00~~$25.00 per share and the exercise price of the stock options that had strike prices below such closing price.

As of ~~June 30,~~December 31, 2023, there was approximately ~~$390~~$479 of total unrecognized compensation expense related to the unvested employee stock options which is expected to be recognized over a weighted average period of ~~2.19~~1.73 years.

Liability classified share-based awards

During the ~~nine~~three months ended ~~June~~December 31, 2023 and fiscal year ended September 30, 2023, ~~7,018~~there were no options granted and no options were ~~granted~~exercised with respect to Indco’s common ~~stock.~~ ~~The Company uses the Black-Scholes option pricing model to estimate the fair value of Indco’s share-based awards. In applying this model, the Company used the following assumptions:~~stock

	~~Nine Months Ended~~ ~~June 30, 2023~~
~~Risk-free interest rate~~		~~3.98~~	%
~~Expected option term in years~~		~~4.5 - 5.5~~
~~Expected volatility~~		44	%
~~Dividend yield~~.		—	%
~~Weighted average grant date fair value~~	$	~~3.96 - $6.68~~

Number
of Options

Weighted
Average
Exercise
Price

Weighted
Average
Remaining
Contractual
Term (in years)

Aggregate
Intrinsic
Value
(in thousands)

Outstanding balance at September 30, 2022
35,607 $ 12.22 6.7 $ 175.98
Granted 7,018 $ 15.20 9.5 $ —
Outstanding balance at June 30, 2023

42,625
$ 12.71 6.6 $ 119.94
Exercisable at June 30, 2023

28,613
$ 11.40 5.5 $ 113.20

The aggregate intrinsic value in the above table was calculated as the difference between the valuation price of Indco’s common stock at June 30, 2023 of $15.20 per share and the exercise price of the stock options that had strike prices below such closing price.

The liability classified awards were measured at fair value at each reporting date until the final measurement date, which was the date of completion of services required to earn the option. The accrued compensation cost related to these options was approximately $340 and $361 as of June 30, 2023 and September 30, 2022, respectively, and is included in other liabilities in the condensed consolidated financial statements. The compensation cost related to these options was approximately $30 and $31 for the nine ~~months ended June 30, 2023 and 2022, respectively.~~

~~The cost associated with the options issued on each grant date is being recognized ratably over the period of service required to earn each tranche of options.~~

1412

Table of Contents

Upon vesting, the options continue to be accounted for as a liability in accordance with ASC 480-10-25-8 and are measured in accordance with ASC 480-10-35 at every reporting period until the options are settled.

~~As a result of previous option exercise and stock repurchase activity, the mandatorily redeemable non-controlling interest percentage was 9.77% as of June 30, 2023.~~

~~Changes in the fair value of the vested options are recognized in earnings in the condensed consolidated financial statements.~~

The options are classified as liabilities, and the underlying shares of Indco’s common stock also contain put options which result in their classification as a mandatorily redeemable security. While their redemption does not occur on a fixed date, there is an unconditional obligation for the Company to repurchase the shares upon death.

~~As of June 30, 2023,~~ there was approximately $57 of total unrecognized compensation expense related to the unvested Indco stock options. This expense is expected to be recognized over a weighted average period of less than one year.

10.	INCOME PER COMMON SHARE

The following table provides a reconciliation of the basic and diluted earnings per share (“EPS”) computations for the three ~~and nine~~ months ended ~~June 30,~~December 31, 2023 and 2022:

	Three Months Ended December 31,
(in thousands, except per share data)	2023			2022
Income:
Net income	$	276		$	360
Preferred stock dividends		(72	)		(72	)
Net income available to common stockholders	$	204		$	288

Common Shares:
Basic - weighted average common shares		1,186.3			1,186.3
Effect of dilutive securities:
Stock options		15.8			21.9
Diluted - weighted average common stock		1,202.1			1,208.2

Income per Common Share:
Basic -
Net income	$	0.23		$	0.30
Preferred stock dividends		(0.06	)		(0.06	)
Net income available to common stockholders	$	0.17		$	0.24

Diluted -
Net income	$	0.23		$	0.30
Preferred stock dividends		(0.06	)		(0.06	)
Net income available to common stockholders	$	0.17		$	0.24

Three Months Ended
June 30,

Nine Months Ended
June 30,

(in thousands, except per share data) 2023

2022
2023
2022

(Loss) Income:
Net (loss) income
$ (430 ) $ 2,158 $ 148 $ 5,119
Preferred stock dividends
(70
)

(71
)

(212
)

(515
)
Non-controlling interest dividends — — — (61 )
Net (loss) income available to common stockholders
$
(500
)

$
2,087

$
(64
)

$
4,543

Common Shares:
Basic - weighted average common shares 1,186.4
1,057.7
1,186.4
996.9

Effect of dilutive securities:
Stock options —
58.9
—
58.0
Convertible preferred stock
—

—

—

0.1

Diluted - weighted average common stock
1,186.4

1,116.6

1,186.4

1,055.0

(Loss) Income per Common Share:
Basic -
Net (loss) income
$ (0.36 ) $ 2.04 $ 0.12 $ 5.13
Preferred stock dividends
(0.06
)

(0.07
)

(0.17
)

(0.51
)
Non-controlling interest dividends
— — — (0.06 )
Net (loss) income available to common stockholders
$
(0.42
)

$
1.97

$
(0.05
)

$
4.56

Diluted -
Net (loss) income
$ (0.36 ) $ 1.93 $ 0.12 $ 4.85
Preferred stock dividends
(0.06
)

(0.06
)

(0.17
)

(0.48
)
Non-controlling interest dividends
— — — (0.06 )
Net (loss) income available to common stockholders
$
(0.42
)

$
1.87

$
(0.05
)

$
4.31

The computation for the diluted number of shares excludes unexercised stock options that are anti-dilutive. There were 22.5 and 10 anti-dilutive shares for ~~each of~~ the ~~three- and nine-month~~three-month periods ended ~~June 30, 2023. There were no anti-dilutive shares for each of the three- and nine-month periods ended June 30, 2023.~~

~~Potentially diluted securities for the three and nine month periods ended June 30,~~December 31, 2023 and 2022, ~~were as follows:~~respectively.

Three Months Ended
June 30,

Nine Months Ended
June 30,

2023

2022
2023
2022
Employee stock options (Note 9) 41 74 41 80

~~Table of Contents~~

11.	INCOME TAXES

The reconciliation of income tax computed at the Federal statutory rate to the provision for income taxes from continuing operations for the ~~three- and nine-month~~three month periods ended ~~June 30,~~December 31, 2023 and 2022 iswas as follows (in thousands):

	Three Months Ended June 30,					Nine Months Ended June 30,						Three Months Ended December 31,
	2023		2022			2023			2022			2023		2022
Federal taxes at statutory rates	$	129	$	(604	)	$	(45	)	$	(1,494	)	$	98	$	107
Permanent differences		31		—			(5	)		—			58		1
State and local taxes, net of Federal benefit		20		(110	)		(18	)		(500	)		36		39
Total income tax benefit (expense)	$	180	$	(714	)	$	(68	)	$	(1,994	)
Total												$	192	$	147

12.	BUSINESS SEGMENT INFORMATION

As referenced above in Note 1, the Company operates in three reportable segments: Logistics, Life Sciences and ~~Manufacturing.~~Manufacturing.

The Company’s Chief Executive Officer regularly reviews financial information at the reporting segment level in order to make decisions about resources to be allocated to the segments and to assess their performance.

Table of Contents

The following tables present selected financial information about the Company’s reportable segments and Corporate for the purpose of reconciling to the consolidated totals for the three months ended December 31, 2023:

For the three months ended December 31, 2023 (in thousands)	Consolidated		Logistics		Life Sciences		Manufacturing		Corporate
Revenues	$	41,035	$	35,215	$	3,481	$	2,339	$	—
Forwarding expenses and cost of revenues		26,890		25,214		606		1,070		—
Gross profit		14,145		10,001		2,875		1,269		—
Selling, general and administrative		12,605		8,865		1,750		784		1,206
Amortization of intangible assets		538		—		—		—		538
Income (loss) from operations		1,002		1,136		1,125		485		(1,744	)
Interest expense		524		357		78		89		—
Identifiable assets		91,502		31,128		11,786		3,875		44,713
Capital expenditures, net of disposals	$	53	$	18	$	35	$	—	$	—

December 31, 2022:

For the three months ended June 30, 2023 (in thousands)	Consolidated		Logistics		Life Sciences		Manufacturing		Corporate
Revenue	$	42,557	$	37,484	$	2,811	$	2,262	$	—
Forwarding expenses and cost of revenue		28,898		27,241		575		1,082		—
For the three months ended December 31, 2022 (in thousands)												Consolidated		Logistics		Life Sciences		Manufacturing		Corporate
Revenues												$	57,044	$	51,800	$	2,838	$	2,406	$	—
Forwarding expenses and cost of revenues													42,127		40,267		728		1,132		—
Gross profit		13,659		10,243		2,236		1,180		—			14,917		11,533		2,110		1,274		—
Selling, general and administrative		12,948		9,629		1,512		717		1,090			13,011		9,528		1,510		774		1,199
Amortization of intangible assets		524		—		—		—		524			526		—		—		—		526
Income (loss) from operations		187		614		724		463		(1,614	)		1,380		2,005		600		500		(1,725	)
Interest expense		528		347		86		95		—			474		334		37		103		—
Identifiable assets		99,566		38,066		11,025		4,228		46,247			111,564		49,220		11,317		4,085		46,942
Capital expenditures, net of disposals	$	89	$	89	$	—	$	—	$	—		$	80	$	68	$	10	$	2	$	—

~~Table of Contents~~

For the nine months ended June 30, 2023
(in thousands)

Consolidated

Logistics

Life Sciences

Manufacturing

Corporate

Revenue $ 144,979 $ 129,162 $ 8,717 $ 7,100 $ —
Forwarding expenses and cost of revenue 102,654 97,339 1,930 3,385 —
Gross profit 42,325 31,823 6,787 3,715 —
Selling, general and administrative 38,261 27,891 4,592 2,267 3,511
Amortization of intangible assets 1,593 — — — 1,593
Income (loss) from operations 2,471 3,932 2,195 1,448 (5,104 )
Interest expense 1,476 1,006 165 305 —
Identifiable assets 99,566 38,066 11,025 4,228 46,247
Capital expenditures, net of disposals $ 267 $ 214 $ 51 $ 2 $ —

~~The following tables present selected financial information about the Company’s reportable segments and Corporate for the purpose of reconciling to the consolidated totals for the~~ ~~three~~ ~~and~~ ~~nine~~ ~~months ended June~~ ~~30,2022~~:

For the three months ended June 30, 2022
(in thousands)

Consolidated

Logistics

Life Sciences

Manufacturing

Corporate

Revenue $ 78,984 $ 73,684 $ 2,738 $ 2,562 $ —
Forwarding expenses and cost of revenue 61,819 59,889 648 1,282 —
Gross profit 17,165 13,795 2,090 1,280 —
Selling, general and administrative 13,505 10,387 1,225 676 1,217
Amortization of intangible assets 489 — — — 489
Income (loss) from operations 3,171 3,408 865 604 (1,706
)
Interest expense 299 242 31 26 —
Identifiable assets 126,106 67,196 12,137 4,363 42,410
Capital expenditures, net of disposals $ 207 $ 171 $ 13 $ 23 $ —

~~Table of Contents~~

For the nine months ended June 30, 2022
(in thousands)

Consolidated

Logistics

Life Sciences

Manufacturing

Corporate

Revenue $ 243,149 $ 226,313 $ 9,257 $ 7,579 $ —
Forwarding expenses and cost of revenue 193,986 187,780 2,516 3,690 —
Gross profit 49,163 38,533 6,741 3,889 —
Selling, general and administrative 39,718 29,802 3,758 2,170 3,988
Amortization of intangible assets 1,485 — — — 1,485
Income (loss) from operations 7,960 8,731 2,983 1,719 (5,473 )
Interest expense 847 683 88 76 —
Identifiable assets 126,106 67,196 12,137 4,363 42,410
Capital expenditures, net of disposals $ 477 $ 260 $ 171 $ 46 $ —

13.	FAIR VALUE MEASUREMENTS

Recurring Fair Value Measurements

The following table presents the Company’s assets that are measured at fair value on a recurring basis based on the three-level valuation hierarchy (in thousands):

Level 1	June 30, 2023		September 30, 2022
Level 1 Assets					December 31, 2023		September 30, 2023
Investment in Rubicon at fair value	$	1,592	$	2,371	$	864	$	1,573

On August 19, 2022, the Company acquired 1,108,000 shares of the common stock, par value $0.001 per share, of Rubicon Technology, Inc. (“Rubicon”), at a price per share of $20.00, in a cash tender offer. As of each of ~~June 30,~~December 31, 2023 and September 30, ~~2022,~~2023, the Company held 46.6% ~~and 44.99%, respectively,~~ of the total issued and outstanding shares of Rubicon and reported its investment under the fair value method pursuant to ASC 320. Management determined that it was appropriate to carry its investment in Rubicon at fair value because the investment was traded on the NASDAQ stock exchange through January 2, 2023, ~~and~~ began trading on the OTCQB Capital Market on January 3, 2023 and had daily trading activity, the combination of which provide a better indicator of value. The investment in Rubicon is re-measured at the end of each quarter based on the trading price and any change in the value is reported on the income statement as an unrealized gain or loss on marketable securities in other income (expense).

On October 4, 2023, Rubicon announced that it had authorized a cash dividend of $1.10 per share of common stock of Rubicon and set October 16, 2023 as the record date for the distribution. On October 23, 2023, the Company received $1,219 in dividends and recorded a fair value adjustment to its investment in Rubicon of $709, which is included in other income and expense.

The following table sets forth a summary of the changes in the fair value of the Company’s investment in Rubicon, which is measured at fair value on a recurring basis utilizing Level 1 assumptions in its valuation (in thousands):

	June 30, 2023			September 30, 2022			December 31, 2023			September 30, 2023
Balance beginning of period	$	2,371		$	—		$	1,573		$	2,371
Purchase of Rubicon Investment		—			22,160
Fair value adjustment to Rubicon investment		(779	)		(19,789	)		(709	)		(798	)
Balance end of period	$	1,592		$	2,371		$	864		$	1,573

Table of Contents

The following table presents the Company’s liabilities that are measured at fair value on a recurring basis based on the three-level valuation hierarchy (in thousands):

Level 3
June 30,
2023

September 30,
2022

Contingent earnout liabilities

$
3,187
$
4,580

	December 31, 2023		September 30, 2023
Level 1 Contingent earnout liabilities	$	2,435	$	—
Level 3 Contingent earnout liabilities		300		2,330
Total	$	2,735	$	2,330

These liabilities relate to the estimated fair value of earnout payments to former IBS and ELFS ~~owners~~Sellers for the periods ending ~~June 30,~~December 31, 2023 and September 30, ~~2022.~~ 2023.

On December 1, 2023, in connection with the Purchase Agreement Amendment among Janel Group and the ELFS Sellers described above, the parties agreed to certain modifications fixing the amount of the remaining earnout payments to ELFS in earnout years three and four to $1,078 each year. As a result the measurement of the earnout liability became a Level 1 fair value measurement based on the present value of the negotiated payments.

The current and non-current portions of the fair value of the contingent earnout ~~liability~~liabilities at ~~June 30,~~December 31, 2023 were ~~$1,209~~$740 and ~~$1,978,~~$1,996, respectively. The current and non-current portions of the fair value of the contingent earnout ~~liability~~liabilities at September 30, ~~2022~~2023 were ~~$1,664~~$592 and ~~$2,916,~~$1,738, respectively.

The following table sets forth a summary of the changes in the fair value of the Company’s contingent earnout liabilities, which are measured at fair value on a recurring basis utilizing Level 3 assumptions in their valuation (in thousands):

	June 30, 2023			September 30, 2022		December 31, 2023			September 30, 2023
Balance beginning of period	$	4,580		$	3,600	$	2,330		$	4,580
Fair value of contingent consideration recorded in connection with business combinations		300			980		—			300
Earnout payment		(1,693	)		—		—			(1,693	)
Fair value adjustment of contingent earnout liabilities							405			(857	)
Transfer to Level 1							(2,435	)		—
Balance end of period	$	3,187		$	4,580	$	300		$	2,330

The Company determined the fair value of the Level 3 contingent earnout liability using forecasted results through the expected earnout periods. The principal inputs to the approach include expectations of the specific business’s revenues in fiscal years 2024 through 2025 using an appropriate discount rate. Given the use of significant inputs that are not observable in the market, the contingent earnout liability is classified within Level 3 of the fair value hierarchy.

~~Table of Contents~~

14.

LEASES

The Company has operating leases for office and warehouse space in ~~certain~~all locations where it conducts business. As of ~~June 30,~~December 31, 2023, the remaining terms of the Company’s operating leases were between one and 75123 months and certain lease agreements contain provisions for future rent increases. Payments due under the lease contracts include the minimum lease payments that the Company is obligated to make under the non-cancelable initial terms of the leases as the renewal terms are at the Company’s option and the Company is not reasonably certain to exercise those renewal options at lease commencement.

The components of lease cost for the ~~three- and nine-month~~three-month periods ended ~~June 30,~~December 31, 2023 and 2022 ~~are~~were as follows (in thousands):

	Three Months Ended June 30,				Nine Months Ended June 30,				Three Months Ended December 31,
	2023		2022		2023		2022		2023			2022
Operating lease cost	$	523	$	457	$	1,540	$	1,370		$	599		$	551
Short-term lease cost		150		123		283		371			100			20
Total lease cost	$	673	$	580	$	1,823	$	1,741		$	699		$	571

Rent expense for the three months ended December 31, 2023 and 2022 was $699 and $571, respectively.

Operating lease right of use assets, current portion of operating lease liabilities and long-term operating lease liabilities reported in the condensed consolidated balance sheets for operating leases as of ~~June 30,~~December 31, 2023 were ~~$6,030, $1,942~~$6,853, $1,935 and ~~$4,318,~~$5,221, respectively.

Operating lease right of use assets, current portion of operating lease liabilities and long-term operating lease liabilities reported in the condensed consolidated balance sheets for operating leases as of September 30, ~~2022~~2023 were $~~5,660, $1,825~~7,460, $2,020 and ~~$4,001,~~$5,689, respectively.

Table of Contents

As of ~~June 30,~~December 31, 2023 and September 30, ~~2022,~~2023, the weighted-average remaining lease term and the weighted-average discount rate related to the Company’s operating leases were ~~4.4~~5.8 years and ~~2.93%~~4.53% and ~~4.6~~5.9 years and ~~3.05%~~4.01%, respectively.

Future minimum lease payments under non-cancelable operating leases as of ~~June 30,~~December 31, 2023 ~~are~~were as follows (in thousands):

2024	$	1,974		$	1,985
2025		1,480			1,523
2026		985			1,193
2027		894			1,215
2028		910			978
Thereafter		424			1,467
Total undiscounted lease payments		6,667
Less imputed interest		(407	)
Total lease obligations	$	6,260
Total undiscounted loan payments					8,361
Less: imputed interest					(1,205	)
Total lease obligation				$	7,156

~~Table of Contents~~

15.	SUBSEQUENT EVENTS

On January 10, 2024, the agreement governing the First Merchants Credit Facilities was amended to provide for, among other changes, permitted affiliate loans, provided that availability on its revolving loan both before and after giving effect to any such loan is not less than $1,000 and the maturity of such permitted affiliate loans are not to exceed fourteen days from disbursement.

Table of Contents

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with our unaudited interim condensed consolidated financial statements and related notes thereto as of and for the three ~~and nine~~ months ended ~~June 30,~~December 31, 2023, which have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). Amounts presented in this section are in thousands, except share and per share data.

As used throughout this Report, “we,” “us”, “our,” “Janel,” “the Company,” “Registrant” and similar words refer to Janel Corporation and its ~~Subsidiaries.~~subsidiaries.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (the “Report”) contains certain statements that are, or may deemed to be, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of ~~1934 and that reflect management’s current expectations with respect to our operations, performance, financial condition, and other developments.~~1934. These forward – looking statements may generally be identified using the words “may,” “will,” “intends,” “plans,” projects,” “believes,” “should,” “expects,” “predicts,” “anticipates,” “estimates,” and similar expressions or the negative of these terms or other comparable terminology. These statements are necessarily estimates reflecting management’s best judgment based upon current information and involve several risks, uncertainties and assumptions. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made, and readers are advised that various factors, including, but not limited to, those set forth elsewhere in this Report, could affect our financial performance and could cause our actual results for future periods to differ materially from those anticipated or projected. While it is impossible to identify all such factors, such factors include, but are not limited to, our strategy of expanding our business through acquisitions of other businesses; we may be required to record a significant charge to earnings related to the impairment of acquired assets; we may fail to realize the expected benefits or strategic objectives of any acquisition, or that we spend resources exploring acquisitions that are not consummated; risks associated with litigation, including contingent auto liability and insurance coverage, and indemnification claims and other unforeseen claims and liabilities that may arise from an acquisition; changes in tax rates, laws or regulations and our ~~acquired companies and subsidiaries’~~ ability to utilize anticipated tax benefits; the impact of ~~inflation and~~ rising interest rates on our investments, business and operations; conflicts of interest with the minority shareholders of our business; ~~economic and other conditions in the markets in which we operate;~~ we may not have sufficient working capital to continue operations; we may lose customers who are not obligated to long-term contracts to transact with us; ~~instability in the financial markets, including in the banking sector;~~ changes or developments in U.S. laws or policies; competition from companies with greater financial resources and from companies that operate in areas in which we plan to expand; our dependence on technically skilled employees; impacts from climate change, including the increased focus by third-parties on sustainability issues and our ability to comply therewith; the impact of ~~increases in shipping costs, long lead times, supply shortages~~evolving corporate governance and ~~supply changes;~~public disclosure regulation; competition from parties who sell their businesses to us and from professionals who cease working for us; terrorist attacks and other acts of violence or war; security breaches or cybersecurity attacks; the impact of catastrophic events, such as health crises, natural disasters and armed conflict; the level of our insurance coverage, including related to product and other liability risks; our compliance with applicable privacy, security and data laws; risks related to the diverse platforms and geographies ~~which~~that host our management information and financial reporting systems; our dependence on the availability of cargo space from third parties; the impact of claims arising from transportation of freight by the carriers with which we contract, including an increase in premium costs; the impact of higher carrier prices; risks related to the classification of owner-operators in the transportation industry; recessions, ~~and other~~ economic developments ~~that reduce freight volumes;~~and other events affecting the volume of international trade and international operations; risks arising from our ability to comply with governmental permit and licensing requirements or statutory and regulatory requirements; environmental laws governing our contracted transportation providers; the impact of seasonal trends ~~impact of lower global volumes due to weak economic conditions~~ and other factors beyond our control on our Logistics business; changes in governmental regulations applicable to our Life Sciences business; the ability of our Life Sciences business to continually produce products that meet high-quality standards such as purity, reproducibility and/or absence of cross-reactivity; the ability of our Life Sciences business to maintain, determine the scope of and defend its and its competitors’ intellectual property rights; the impact of pressures in the life sciences industry to increase the predictability of or reduce healthcare costs; any decrease in the availability, or increase in the cost or supply shortages, of raw materials used by Indco; risks arising from the environmental, health and safety regulations applicable to Indco; the reliance of our Indco business on a single location to manufacture their products; the controlling influence exerted by ~~our officers and directors and one~~a small number of our stockholders; the unlikelihood that we will issue dividends in the foreseeable future; and risks related to ownership of our common stock, including share price volatility, the lack of a guaranteed continued public trading market for our common stock, our ability to issue shares of preferred stock with greater rights than our common stock and costs related to maintaining our status as a public company; and such other factors that may be identified from time to time in our filings with the Securities and Exchange Commission (“SEC”) ~~filings.~~. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those projected. You should not place undue reliance on any of our forward-looking statements which speak only as of the date they are made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For a more detailed discussion of these factors, see our periodic reports filed with the SEC, including our most recent Annual Report on Form 10-K for the fiscal year ended September 30, ~~2022.~~2023.

2017

Table of Contents

OVERVIEW

Janel Corporation ("(“Janel,"” the ~~"Company,"~~“Company,” or the ~~"Registrant"~~“Registrant”) is a holding company with subsidiaries in three business segments: Logistics, Life Sciences and Manufacturing. The Company strives to create shareholder value primarily through three strategic priorities: supporting its businesses’ efforts to make investments and to build long-term profits; allocating ~~Janel's~~Janel’s capital at high risk-adjusted rates of return; and attracting and retaining exceptional talent.

Management at the Janel holding company focuses on significant capital allocation decisions, corporate governance and supporting Janel’s subsidiaries where appropriate. Janel expects to grow through its subsidiaries’ organic growth and by completing acquisitions. We plan to either acquire businesses within our existing segments or expand our portfolio into new strategic segments. Our acquisition strategy focuses on ~~reasonably priced~~reasonably-priced companies with strong and capable management teams, attractive existing business economics and stable and predictable earnings power.

Logistics

The Company’s Logistics segment is comprised of several wholly-owned subsidiaries. The Logistics segment is a non-asset based, full-service provider of cargo transportation logistics management services, including freight forwarding via air, ocean and land-based carriers; customs brokerage services; warehousing and distribution services; trucking and other value-added logistics services. In addition to these revenue streams, the Company earns accessorial ~~revenue~~revenues in connection with its core services. Accessorial ~~revenue includes,~~revenues include, but isare not limited to, fuel service charges, wait time fees, hazardous cargo fees, labor charges, handling, cartage, bonding and additional labor charges.

~~Table of Contents~~

Life Sciences

The Company’s Life Sciences segment is comprised of several wholly-owned subsidiaries. The Company’s Life Sciences segment manufactures and distributes high-quality monoclonal and polyclonal antibodies, diagnostic reagents and other immunoreagents for biomedical research and provides antibody manufacturing for academic and industry research scientists. Our Life Sciences segment also produces products for other life science companies on an original equipment manufacturer (OEM) basis.

On May 22, 2023, the Company acquired all the rights, title and interests to a royalty agreement for certain antibody products, which we include in our Life Sciences segment.

On March 2, 2023, the Company completed a business combination whereby it acquired all of the outstanding stock of Stephen Hall, PhD Ltd., which we include in our Life Sciences segment.

On November 1, 2022, the Company completed a business combination whereby it acquired all of the outstanding stock of ImmunoBioScience Corporation, which we include in our Life Sciences segment.

~~On August 15, 2022, the Company completed a business combination whereby it acquired all the membership interests of ECM Biosciences LLC, which we include in our Life Sciences segment.~~

Manufacturing

The Company’s Manufacturing segment is comprised of Indco, Inc. (“Indco”). Indco is a majority-owned subsidiary of the Company that manufactures and distributes mixing equipment and apparatus for specific applications within various industries. Indco’s customer base is comprised of small- to mid-sized businesses as well as other larger customers for which Indco fulfills repetitive production orders.

Investment in Marketable Securities - Rubicon

On August 19, 2022, the Company acquired 1,108,000 shares of the common stock, par value $0.001 per share, of Rubicon Technology, Inc. ~~("Rubicon"~~(“Rubicon”), at a price per share of $20.00, in a cash tender offer made pursuant to the Stock Purchase and Sale Agreement, dated July 1, 2022, between the Company and Rubicon (the ~~"Rubicon~~“Rubicon Purchase ~~Agreement"~~Agreement”). Pursuant to the terms of the Rubicon Purchase Agreement, the acquired shares represented ~~44.99%~~45.0% of ~~Rubicon's~~Rubicon’s issued and outstanding shares of common stock as of August 3, 2022, as reported in ~~Rubicon's~~Rubicon’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022, filed with the SEC on August 12, 2022. On October 4, 2023, Rubicon announced that it had authorized a cash dividend of $1.10 per share of common stock of Rubicon and set October 16, 2023 as the record date for the distribution. On October 23, 2023, the Company received $1,219 in dividends. The Company owned approximately 46.6% of ~~Rubicon's~~Rubicon’s issued and outstanding shares of common stock as of ~~June~~each of December 31, 2023 and September 30, 2023.

Rubicon is an advanced materials provider specializing in monocrystalline sapphire for applications in optical and industrial systems. The purpose of our investment in Rubicon is for Janel to acquire a significant ownership interest in Rubicon, together with representation on ~~Rubicon's Board,~~Rubicon’s board, in an attempt to (i) restructure the Rubicon business to achieve profitability and (ii) assist Rubicon in utilizing its net operating loss carry-forward assets. Although we are optimistic about our investment in Rubicon, our investment involves risks and uncertainties that are beyond our control.

Table of Contents

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States. These generally accepted accounting principles require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net sales and expenses during the reporting period.

Our senior management has reviewed the critical accounting policies and estimates with the ~~Audit Committee~~audit committee of our ~~Board~~board of ~~Directors.~~directors. For a description of the Company’s critical accounting policies and estimates, refer to “Part II—Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Estimates” in our Annual Report on Form 10-K filed with the SEC on December ~~9, 2022.~~8, 2023. Critical accounting policies are those that are most important to the portrayal of our financial condition, results of operations and cash flows and require management’s most difficult, subjective and complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. If actual results were to differ significantly from estimates made, the reported results could be materially affected. There were no significant changes to our critical accounting policies during the ~~nine~~three months ended ~~June 30,~~December 31, 2023.

NON-GAAP FINANCIAL MEASURES

While we prepare our financial statements in accordance with U.S. GAAP, we also utilize and present certain financial measures, in particular adjusted operating income, which is not based on or included in U.S. GAAP (we refer to these as “non-GAAP financial measures”).

~~Table of Contents~~

Organic ~~Revenue~~Growth

Our non-GAAP financial measure of organic ~~revenue~~growth represents revenue growth excluding ~~revenue~~revenues from acquisitions within the preceding 12 months.

The organic ~~revenue~~growth presentation provides useful period-to-period comparison of revenue results as it excludes ~~revenue~~revenues from acquisitions that would not be included in the comparable prior period.

Adjusted Operating Income

As a result of our acquisition strategy, our net income includes material non-cash charges relating to the amortization of customer-related intangible assets in the ordinary course of business as well as other intangible assets acquired in our acquisitions. Although these charges may increase as we complete more acquisitions, we believe we will be growing the value of our intangible assets such as customer relationships. Because these charges are not indicative of our operations, we believe that adjusted operating income is a useful financial measure for investors because it eliminates the effect of these non-cash costs and provides an important metric for our business that is more representative of the actual results of our operations.

Adjusted operating income (which excludes the non-cash impact of amortization of intangible assets, stock-based compensation and cost recognized on the sale of acquired inventory valuation) is used by management as a supplemental performance measure to assess our business’s ability to generate cash and economic returns.

Adjusted operating income is a non-GAAP measure of income and does not include the effects of preferred stock dividends, interest and taxes.

We believe that organic ~~revenue~~growth and adjusted operating income provide useful information in understanding and evaluating our operating results in the same manner as management. However, organic ~~revenue~~growth and adjusted operating income are not financial measures calculated in accordance with U.S. GAAP and should not be considered as a substitute for total ~~revenue,~~revenues, operating income or any other operating performance measures calculated in accordance with U.S. GAAP. Using these non-GAAP financial measures to analyze our business has material limitations because the calculations are based on the subjective determination of management regarding the nature and classification of events and circumstances that users of the financial statements may find significant.

In addition, although other companies may report measures titled organic ~~revenue,~~growth, adjusted operating income or similar measures, such non-GAAP financial measures may be calculated differently from how we calculate our non-GAAP financial measures, which reduces their overall usefulness as comparative measures. Because of these limitations, you should consider organic ~~revenue~~growth and adjusted operating income alongside other financial performance measures, including total ~~revenue,~~revenues, operating income and our other financial results presented in accordance with U.S. GAAP.

Results of Operations – Janel Corporation -– Three ~~and Nine~~ Months Ended ~~June 30,~~December 31, 2023 and 2022

Our results of operations and period-over-period changes are discussed in the following section. The tables and discussion should be read in conjunction with the accompanying Condensed Consolidated Financial Statements and the notes thereto.

Table of Contents

Our consolidated results of operations are as follows:

	Three Months Ended June 30,					Nine Months Ended June 30,				Three Months Ended December 31,
(in thousands)	2023			2022		2023		2022		2023		2022
Revenue	$	42,557		$	78,984	$	144,979	$	243,149
Forwarding expenses and cost of revenue		28,898			61,819		102,654		193,986
Revenues										$	41,035	$	57,044
Forwarding expenses and cost of revenues											26,890		42,127
Gross profit		13,659			17,165		42,325		49,163		14,145		14,917
Operating expenses		13,472			13,994		39,854		41,203		13,143		13,537
Income from operations		187			3,171		2,471		7,960		1,002		1,380
Net (loss) income		(430	)		2,158		148		5,119
Net income											276		360
Adjusted operating income	$	876		$	3,822	$	4,569	$	10,638	$	1,694	$	2,057

Consolidated ~~revenue~~revenues for the three months ended ~~June 30,~~December 31, 2023 ~~was $42,557,~~were $41,035, which was ~~$36,427~~$16,009 or ~~46.1%~~28% lower than the prior year period. ~~Consolidated revenue for the nine months ended June 30, 2023 was $144,979, which was $98,170 or 40.4% lower than the prior year period. Revenue for both the three and nine monthsended June 30, 2023~~Revenues over this period decreased primarily due to lower freight prices in our Logistics segment as ~~a result of~~ lower freight demand ~~relative to improved~~aligned more closely with global transportation capacity.

~~Table of Contents~~

Income from operations for the three months ended ~~June 30,~~December 31, 2023 was ~~$187~~$1,002 compared with ~~$3,171 in the prior year period. Income from operations for the nine months ended June 30, 2023 was $2,471 compared with$7,960~~$1,380 in the prior year period. The decrease for ~~both~~ the three ~~and nine~~ months ended ~~June 30,~~December 31, 2023 resulted from lower profits ~~across our business segments, especially at~~primarily in our Logistics ~~segment, which benefited from unusually high demand in the prior year periods.~~segment.

Net ~~loss~~income for the three months ended ~~June 30,~~December 31, 2023 totaled ~~($430)~~$276 or ~~($0.36)~~$0.23 per diluted share, compared to net income of ~~$2,158~~$360 or ~~$1.93~~$0.30 per diluted share for the three months ended June 30, 2022. Net income for the nine months ended June 30, 2023 totaled $148 or $0.12 per diluted share, compared to net income of $5,119 or $4.85 per diluted share for the nine months ended June 30,December 31, 2022. The decline in net income was largely due to lower profits primarily in our ~~business segments,~~Logistics segment, higher interest expense and a non-cash mark-to-market write-down of anour equity investment.

Adjusted operating income for the three months ended ~~June 30,~~December 31, 2023 ~~decreased to $876~~was $1,694, a decrease of $363 versus ~~$3,822 in the prior year period. Adjusted operating income for the nine months ended June 30, 2023 decreased to $4,569 versus $10,638~~$2,057 in the prior year period. The decrease for ~~both~~ the three ~~and nine~~ months ended ~~June 30,~~December 31, 2023 resulted primarily from a decline in profits in our Logistics segment partially offset by an ~~overall decrease~~increase in profits at our ~~business segments.~~Life Sciences business.

The following table sets forth a reconciliation of operating income to adjusted operating income:

	Three Months Ended June 30,				Nine Months Ended June 30,				Three Months Ended December 31,
(in thousands)	2023		2022		2023		2022		2023		2022
Income from operations	$	187	$	3,171	$	2,471	$	7,960	$	1,002	$	1,380
Amortization of intangible assets		524		489		1,593		1,485		538		526
Stock-based compensation		62		32		185		800		71		61
Cost recognized on sale of acquired inventory		103		130		320		393		83		90
Adjusted operating income	$	876	$	3,822	$	4,569	$	10,638	$	1,694	$	2,057

Results of Operations – Logistics – Three ~~and Nine~~ Months Ended ~~June 30,~~December 31, 2023 and 2022

Our Logistics business helps its clients move and manage freight efficiently to reduce inventories and to increase supply chain speed and reliability. Key services include arrangement of freight forwarding by air, ocean and ground, customs entry filing, warehousing, cargo insurance procurement, logistics planning, product repackaging and online shipment tracking.

	Three Months Ended June 30,						Nine Months Ended June 30,						Three Months Ended December 31,
	2023			2022			2023			2022			2023			2022
(in thousands)
Revenue	$	37,484		$	73,684		$	129,162		$	226,313
Forwarding expense		27,241			59,889			97,339			187,780
Revenues													$	35,215		$	51,800
Forwarding expenses														25,214			40,267
Gross profit		10,243			13,795			31,823			38,533			10,001			11,533
Gross profit margin		27.3	%		18.7	%		25.7	%		17.0	%		28.4	%		22.3	%
Selling, general and administrative expenses		9,629			10,387			27,891			29,802			8,865			9,528
Income from operations	$	614		$	3,408		$	3,932		$	8,731		$	1,136		$	2,005

~~Revenue~~Revenues

Total ~~revenue~~revenues for the three months ended ~~June 30,~~December 31, 2023 ~~was $37,484~~were $35,215 as compared to ~~$73,684~~$51,800 for the three months ended ~~June 30,~~December 31, 2022, a decrease of ~~$36,200,~~$16,585 or ~~49.1%~~32%. ~~Total revenue for the nine months ended June 30, 2023 was $129,162 as compared to $226,313 for the nine months ended June 30, 2022, a decrease of $97,151 or 42.9%. Revenue~~Revenues decreased ~~for both the three and nine months ended June 30, 2023~~ primarily due to ~~lower freight prices~~a reduction in transportation rates as ~~a result of~~ lower freight demand ~~relative to improved~~aligned more closely with global transportation capacity.

Table of Contents

Gross Profit

Gross profit for the three months ended ~~June 30,~~December 31, 2023 was ~~$10,243,~~$10,001, a decrease of ~~$3,552,~~$1,532, or ~~25.7%~~13%, as compared to ~~$13,795~~$11,533 for the three months ended ~~June 30,~~December 31, 2022. Gross ~~profit~~ margin as a percentage of ~~revenue~~revenues increased to ~~27.3%~~28.4% for the three months ended ~~June 30,~~December 31, 2023, compared to ~~18.7%~~22.3% for the prior year period, ~~primarily because gross profit~~as forwarding expenses declined ~~at a slower rate as compared to gross revenue, which declined more significantly due to lower~~in line with transportation freight ~~prices.~~rates.

Gross profit for the nine months ended June 30, 2023 was $31,823, a decrease of $6,710, or 17.4%, as compared to $38,533 for the nine months ended June 30, 2022. Gross profit margin as a percentage of revenue increased to 25.7% compared to 17.0% for the prior year period, primarily because gross profit declined at a slower rate compared with gross revenue, which declined more significantly due to lower freight prices.

~~Table of Contents~~

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the three months ended ~~June 30,~~December 31, 2023 were ~~$9,629,~~$8,865, as compared to ~~$10,387~~$9,528 for the three months ended ~~June 30,~~December 31, 2022. This decrease of ~~$758,~~$633, or ~~7.3%~~7%, was mainly due to lower personnel expenses and a recovery of previously expensed bad ~~debt expense. Selling,~~debt. As a percentage of revenues, selling, general and administrative expenses ~~as a percentage~~were 25.2% and 18.4% of ~~revenue were 25.7% and 14.1%~~revenues for the three months ended ~~June 30,~~December 31, 2023 and 2022, respectively. The increase in selling, general and administrative expenses as a percentage of ~~revenue largely reflected the reduction in transportation rates.~~

Selling, general and administrative expenses for the nine months ended June 30, 2023 were $27,891, as compared to $29,802 for the nine months ended June 30, 2022. This decrease of $1,911, or 6.4%, was mainly due to lower personnel expenses and recovery of bad debt expense. Selling, general and administrative expenses as a percentage of revenue were 21.6% and 13.2% of revenue for the nine months ended June 30, 2023 and 2022, respectively. The increase in selling, general and administrative expenses as a percentage of revenuerevenues largely reflected the decrease in transportation ~~rates.~~rates and its impact on revenues.

Income from Operations

Income from operations decreased to ~~$614~~$1,136 for the three months ended ~~June 30,~~December 31, 2023, as compared to income from operations of ~~$3,408~~$2,005 for the three months ended ~~June 30,~~December 31, 2022, a decrease of ~~$2,794, or 81.9%.~~$869. Income from operations decreased as a result of lower transportation ~~demand.~~volume and prices partially offset by lower personnel expense. Operating margin as a percentage of gross profit for the three months ended ~~June 30,~~December 31, 2023 was ~~6.0%~~11.4% compared to ~~24.7% in the prior year period due to lower gross profits.~~

Income from operations decreased to $3,932 for the nine months ended June 30, 2023, as compared to $8,731 for the nine months ended June 30, 2022, a decrease of $4,799, or 55.0%. Income from operations decreased during the nine months ended June 30, 2023 as a result of lower transportation demand. Our operating margin as a percentage of gross profit for the nine months ended June 30, 2023 was 12.4% compared to 22.7%17.4% in the prior year period, largely due to lower gross profits.

Results of Operations – Life Sciences – Three ~~and Nine~~ Months Ended ~~June 30,~~December 31, 2023 and 2022

The Company’s Life Sciences segment manufactures and distributes high-quality monoclonal and polyclonal antibodies, diagnostic reagents and other immunoreagents for biomedical research and provides antibody manufacturing for academic and industry research scientists. Our Life Sciences business also produces products for other life science companies on an OEM basis.

Three Months Ended
June 30,

Nine Months Ended
June 30,

2023 2022 2023 2022
(in thousands)
Revenue $ 2,811 $ 2,738 $ 8,717 $ 9,257
Cost of sales 472 518 1,610 2,123
Cost recognized upon sale of acquired inventory 103 130 320 393
Gross profit 2,236 2,090 6,787 6,741
Gross profit margin 79.5 % 76.3 % 77.9 % 72.8 %
Selling, general and administrative 1,512 1,225 4,592 3,758
Income from operations $ 724 $ 865 $ 2,195 $ 2,983

Life Sciences – Selected Financial Information:

	Three Months Ended December 31,
	2023			2022
(in thousands)
Revenues	$	3,481		$	2,838
Cost of sales		523			638
Cost recognized upon sale of acquired inventory		83			90
Gross profit		2,875			2,110
Gross profit margin		82.6	%		74.3	%
Selling, general and administrative expenses		1,750			1,510
Income from operations	$	1,125		$	600

~~Revenue~~Revenues

Total ~~revenue was $2,811~~revenues were $3,481 and ~~$2,738~~$2,838 for the three months ended ~~June 30,~~December 31, 2023 and 2022, respectively, reflecting ~~a slight~~an increase of ~~$73,~~$643 or ~~2.7%,~~23% compared to the prior year period, primarily due to ~~current year acquistions, partially offset by lower demand~~the timing of orders, in particular for diagnostic reagents. Organic ~~revenue excluding acquisition revenue~~ ~~declined $251, or 9.2%.~~

~~Total revenue was $8,717 and $9,257~~growth for the ~~nine~~three months ended ~~June 30,~~December 31, 2023 ~~and 2022, respectively, reflecting a decrease of $540,~~increased $558 or ~~5.8%, compared to~~20% from the prior year period ~~due to lower demand for~~excluding acquired revenues of $85, as diagnostic ~~reagents, partially offset by current year acquisitions.~~ ~~Organic revenue excluding acquisition revenue~~ ~~declined $1,239, or 13.8%.~~reagent orders recovered from prior-year inventory adjustments.

~~Table of Contents~~

Gross Profit

Gross profit was ~~$2,236~~$2,875 and ~~$2,090~~$2,110 for the three months ended ~~June 30,~~December 31, 2023 and 2022, respectively, an increase of ~~$146,~~$765 or ~~7.0%~~36.3%. During the three months ended ~~June 30,~~December 31, 2023 and 2022, gross profit margin was ~~79.5%~~82.6% and ~~76.3%~~74.3%, respectively, as cost recognized upon sale of acquired inventory declined slightly and product mix ~~improved.~~

Gross profit was $6,787 and $6,741 for the nine months ended June 30, 2023 and 2022, respectively, an increase of $46 or 0.7%. During the nine months ended June 30, 2023 and 2022, the Life Sciences segment had gross profit margin of 77.9% and 72.8%, respectively. The increase in gross profit margin resultedimproved due to contributions from ~~an improvement in product mix.~~past acquisitions.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the Life Sciences segment were ~~$1,512~~$1,750 and ~~$1,225~~$1,510 for the three months ended ~~June 30, 2023 and 2022, respectively. Selling, general and administrative expenses were $4,592 and $3,758 for the nine months ended June 30,~~December 31, 2023 and 2022, respectively. The year-over-year ~~increases for both periods were~~increase was largely due to ~~additional~~personnel expenses ~~from acquired businesses.~~and investments to support growth.

Table of Contents

Income from Operations

Income from operations for the three months ended ~~June 30,~~December 31, 2023 and 2022 was ~~$724~~$1,125 and ~~$865,~~$600, respectively, ~~a decrease~~an increase of ~~$141,~~$525 or ~~16.3%. Income from operations for~~87.5%, due to the ~~nine months ended June 30, 2023 and 2022 was $2,195 and $2,983, respectively, a decrease~~timing of ~~$788, or 26.4%. Both the three-month and nine-month periods were impacted by lower demand~~orders, in particular for diagnostic ~~reagents and additional expenses from acquired businesses.~~reagents.

Results of Operations - Manufacturing – Three ~~and Nine~~ Months Ended ~~June 30,~~December 31, 2023 and 2022

The Company’s Manufacturing segment reflects its majority-owned Indco subsidiary, which manufactures and distributes industrial mixing equipment.

Three Months Ended
June 30,

Nine Months Ended
June 30,

2023 2022 2023 2022
(in thousands)
Revenue $ 2,262 $ 2,562 $ 7,100 $ 7,579
Cost of sales 1,082 1,282 3,385 3,690
Gross profit 1,180 1,280 3,715 3,889
Gross profit margin 52.2 % 50.0 % 52.3 % 51.3 %
Selling, general and administrative expenses 717 676 2,267 2,170
Income from operations $ 463 $ 604 $ 1,448 $ 1,719

Manufacturing – Selected Financial Information:

	Three Months Ended December 31,
	2023			2022
(in thousands)
Revenues	$	2,339		$	2,406
Cost of sales		1,070			1,132
Gross profit		1,269			1,274
Gross profit margin		54.3	%		53.0	%
Selling, general and administrative expenses		784			774
Income from operations	$	485		$	500

~~Revenue~~Revenues

Total ~~revenue was $2,262~~revenues were $2,339 and ~~$2,562~~$2,406 for the three months ended ~~June 30,~~December 31, 2023 and 2022, respectively, a decrease of ~~$300,~~$67 or ~~11.7%. Total revenue was $7,100 and $7,579 for the nine months ended June 30, 2023 and 2022, respectively, a decrease of $479, or 6.3%~~3%. The decrease in ~~revenue~~revenues for ~~both~~ the three ~~and nine~~ months ended ~~June 30,~~December 31, 2023 primarily reflected a slight decrease in volume across the business offset in part by higher product pricing.

Gross Profit

Gross profit was ~~$1,180~~$1,269 and ~~$1,280~~$1,274 for the three months ended ~~June 30,~~December 31, 2023 and 2022, respectively, a decrease of ~~$100, or 7.8%.~~$5. Gross profit margin for the three months ended ~~June 30,~~December 31, 2023 and 2022 was ~~52.2%~~54.3% and 50.0%, respectively. Gross profit was $3,715 and $3,889 for the nine months ended June 30, 2023 and 2022, respectively, a decrease of $174, or 4.5%. Gross profit margin for the nine months ended June 30, 2023 and 2022 was 52.3% and 51.3%53.0%, respectively. The ~~gross profit and~~modest year-over-year increase in gross profit margin ~~for both~~was generally due to the ~~three- and nine-month periods remained relatively unchanged.~~mix of business.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were ~~$717~~$784 and ~~$676~~$774 for the three months ended ~~June 30,~~December 31, 2023 and 2022, respectively, an increase of ~~$41,~~$10 or ~~6.1%. Selling, general and administrative expenses were $2,267 and $2,170 for the nine months ended June 30, 2023 and 2022, respectively, an increase of $97, or 4.5%~~1%. The modest increase in expenses relative to ~~revenue~~revenues for the ~~three- and nine-month~~three-month periods reflected the mix of business.

~~Table of Contents~~

Income from Operations

Income from operations was ~~$463~~$485 for the three months ended ~~June 30,~~December 31, 2023 compared to ~~$604~~$500 for the three months ended ~~June 30,~~December 31, 2022, representing a ~~23.3%~~3% decrease from the prior year period ~~due to unfavorable order timing versus~~as a result of the prior year period. Income from operations was $1,448 for the nine months ended June 30, 2023 compared to $1,719 for the nine months ended June 30, 2022, representing a 15.8% decrease from the prior year period due to unfavorable order timing versus the prior year period.factors set forth above.

Results of Operations – Corporate and Other – Three ~~and Nine~~ Months Ended ~~June 30,~~December 31, 2023 and 2022

Below is a reconciliation of income from operating segments to net income available to common stockholders.

	Three Months Ended June 30,						Nine Months Ended June 30,						Three Months Ended December 31,
(in thousands)	2023			2022			2023			2022			2023			2022
Total income from operations by segment	$	1,801		$	4,877		$	7,575		$	13,433		$	2,746		$	3,105
Corporate expenses		(1,028	)		(1,185	)		(3,326	)		(3,188	)		(1,135	)		(1,138	)
Amortization of intangible assets		(524	)		(489	)		(1,593	)		(1,485	)		(538	)		(526	)
Stock-based compensation		(62	)		(32	)		(185	)		(800	)		(71	)		(61	)
Total corporate expenses		(1,614	)		(1,706	)		(5,104	)		(5,473	)		(1,744	)		(1,725	)
Interest expense		(528	)		(299	)		(1,476	)		(847	)		(524	)		(474	)
Fair value adjustments to Rubicon investment		(269	)		—			(779	)		—
Net (loss) income before taxes		(610	)		2,872			216			7,113
Income tax benefit (expense)		180			(714	)		(68	)		(1,994	)
Net (loss) Income		(430	)		2,158			148			5,119
Fair value adjustments to Rubicon investment (net of dividends)														510			(399	)
Fair value adjustment of contingent earnout liabilities														(395	)		—
Gain on extinguishment														21			—
Change in fair value of mandatorily redeemable non-controlling interest														(146	)		—
Net income before taxes														468			507
Income tax expense														(192	)		(147	)
Net Income														276			360
Preferred stock dividends		(70	)		(71	)		(212	)		(515	)		(72	)		(72	)
Non-controlling interest dividend		—			—			—			(61	)
Net (loss) Income Available to Common Stockholders	$	(500	)	$	2,087		$	(64	)	$	4,543
Net Income Available to Common Stockholders													$	204		$	288

Table of Contents

Total Corporate Expenses

Total Corporate expenses, which include amortization of intangible assets, stock-based compensation and merger and acquisition expenses, ~~decreased~~increased by ~~$92,~~$19, or ~~5.4%~~1%, to ~~$1,614~~$1,744 in the three months ended ~~June 30,~~December 31, 2023 as compared to ~~$1,706~~$1,725 for the three months ended ~~June 30,~~December 31, 2022. Total Corporate expenses decreased by $369, or 6.7%, to $5,104 for the nine months ended June 30, 2023 as compared to $5,473 for the nine months ended June 30, 2022. The decrease in both periods was due primarily to higher stock-based compensation related to restricted stock issuance with immediate vesting, higher accounting-related professional expense, and increased merger and acquisition expenses in the prior year periods partially offset by current year increases in amortization of intangible expenses. We incur merger and acquisition deal-related expenses and intangible amortization at the Corporate level rather than at the segment level.

Interest Expense

Interest expense for the consolidated company increased ~~$229,~~$50 or ~~76.6%~~11%, to ~~$528~~$524 for the three months ended ~~June 30,~~December 31, 2023 from ~~$299~~$474 for the three months ended ~~June 30, 2022. Interest expense for the consolidated company increased by $629, or 74.3%, to $1,476 for the nine months ended June 30, 2023 from $847 for the nine months ended June 30,~~December 31, 2022. The increase ~~in both periods~~ was primarily due to higher interest rates partially ~~off-set~~offset by lower average debt ~~outstanding.~~balances.

Income Tax Expense

On a consolidated basis, the Company recorded an income tax benefit of $180, an effective tax rate of 29.5% for the three months ended June 30, 2023, as compared to an income tax expense of $714, an effective tax rate of 24.9% for the three months ended June 30, 2022. On a consolidated basis, the Company recorded an income tax expense of ~~$68, an effective tax rate of 31.5%~~ $192for the ~~nine~~three months ended ~~June 30,~~December 31, 2023, as compared to an income tax expense of ~~$1,994, an effective tax rate of 28.0%~~$147 for the ~~nine~~three months ended ~~June 30,~~December 31, 2022. The ~~rate was higher than the statutory rate of 21%~~increase in ~~both periods due to non-deductible expenses and state~~ income ~~taxes. The decrease in~~tax expense ~~for both periods~~ was primarily due to ~~a decrease in pretax~~higher taxable income.

Preferred Stock Dividends

Preferred stock dividends include any dividends accrued but not paid on the Company’s Series C Cumulative Preferred Stock (the “Series C Preferred Stock”). For each of the three months ended ~~June 30,~~December 31, 2023 and 2022, preferred stock dividends were $70 and $71, respectively, representing a decrease of $1, or 1.4%. For the nine months ended June 30, 2023 and 2022, preferred stock dividends were $212 and $515, respectively, representing a decrease of $303, or 58.8%. The decrease in preferred stock dividends in both periods was the result of the Company retiring $6,000 of Series C Preferred Stock on March 31, 2022 and the change in the annual dividend rate from 9% to 5% at that time.$72.

~~Table of Contents~~

Net ~~(Loss)~~ Income

Net ~~loss~~income was ~~($430),~~$276, or ~~($0.36)~~$0.23 per diluted share, for the three months ended ~~June 30,~~December 31, 2023 compared to net income of ~~$2,158~~$360, or ~~$1.93~~$0.30 per diluted share, for the three months ended ~~June 30, 2022.~~

~~Net income was $148, or $0.12 per diluted share, for the nine months ended June 30, 2023 compared to net income of $5,119, or $4.85 per diluted share, for the nine months ended June 30,~~December 31, 2022. The decline in net income ~~in both periods~~ was largely due to lower profits in our business segments, higher interest expenses, a non-cash charge resulting from a change to the ELFS earnout liability and fair value adjustment to the mandatorily redeemable non-controlling interest, offset by a non-cash mark-to-market write-down of an equity investment.

~~Net (Loss)~~ Income Available to Common Stockholders

~~Net (loss)~~Income available to holders of ~~Common Stock~~common stock was ~~($500),~~$204, or ~~($0.42)~~$0.17 per diluted share, for the three months ended ~~June 30,~~December 31, 2023 compared to ~~net~~ income available to holders of ~~Common Stock~~common stock of ~~$2,087,~~$288, or ~~$1.87~~$0.24 per diluted share, for the three months ended June 30, 2022. Net (loss) available to holders of Common Stock was ($64), or ($0.05) per diluted share, for the nine months ended June 30, 2023 compared to income available to holders of Common Stock of $4,543, or $4.31 per diluted share, for the nine months ended June 30,December 31, 2022. The decrease in net income available to common stockholders ~~for both periods~~ reflected lower net ~~income and a decrease in the dividend rate with respect to the Series C Preferred Stock as of March 31, 2022 from 9% to 5%.~~income.

LIQUIDITY AND CAPITAL RESOURCES

General

Our ability to satisfy liquidity requirements—including meeting debt obligations and funding working capital, day-to-day operating expenses, and capital expenditures—depends upon future performance, which is subject to general economic conditions, competition and other factors, some of which are beyond our control. Our Logistics segment depends on commercial credit facilities to fund day-to-day operations as there is a difference between the timing of collection cycles and the timing of payments to vendors.

As a customs broker, our Logistics segment makes significant cash advances for a select group of our credit-worthy customers. These cash advances are for customer obligations such as the payment of duties and taxes to customs authorities primarily in the United States. Increases in duty rates could result in increases in the amounts we advance on behalf of our customers. Cash advances are a “pass through” and are not recorded as a component of ~~revenue~~revenues and ~~expense.~~expenses. The billings of such advances to customers are accounted for as a direct increase in accounts receivable from the customer and a corresponding increase in accounts payable to governmental customs authorities. These “pass through” billings can influence our traditional credit collection metrics.

For customers that meet certain criteria, we have agreed to extend payment terms beyond our customary terms. Management believes that it has established effective credit control procedures and has historically experienced relatively insignificant collection problems. Our subsidiaries depend on commercial credit facilities to fund day-to-day operations as there is a difference between the timing of collection cycles and the timing of payments to vendors. Generally, we do not make significant capital expenditures.

Table of Contents

Our cash flow performance for the 2023 fiscal year may not necessarily be indicative of future cash flow performance.

Cash flows from operating activities

Net cash provided by operating activities was ~~$11,056~~$3,006 for the ~~nine~~three months ended ~~June 30,~~December 31, 2023, versus ~~$8,678 provided by operating activities~~$5,780 for the ~~nine~~three months ended ~~June 30,~~December 31, 2022. The ~~increase~~decrease in cash provided by operations for the ~~nine~~three months ended ~~June 30,~~December 31, 2023 compared to the prior year period was driven principally by a lower net working capital benefit at our Logistics ~~segment, partially offset by a decline in net income.~~segment.

Cash flows from investing activities

Net cash used in investing activities totaled ~~$6,361~~$53 for the ~~nine~~three months ended ~~June 30,~~December 31, 2023, versus ~~$589~~$2,927 for the ~~nine~~three months ended ~~June 30,~~December 31, 2022. We used $267 for the acquisition of property and equipment, $1,693 in earnout payment to the former owners of ELFS and $4,401 for the acquisition of two business for the nine months ended June 30, 2023, compared to $477$53 for the acquisition of property and equipment for the ~~nine~~three months ended ~~June 30,~~December 31, 2023, compared to $80 for the acquisition of property and equipment and $2,847 for the acquisition of one business for the three months ended December 31, 2022.

Cash flows from financing activities

Net cash used in financing activities was ~~$8,513~~ $3,835for the ~~nine~~three months ended ~~June 30,~~December 31, 2023, versus net cash used in financing activities of ~~$10,487~~$5,289 for the ~~nine~~three months ended ~~June 30,~~December 31, 2022. Net cash used in financing activities for the ~~nine~~three months ended ~~June 30,~~December 31, 2023 ~~primarily~~ included repayment of funds from our ~~line~~lines of credit, ~~and~~ repayment of funds from our term ~~loan.~~loan and repayment of subordinated promissory notes. Net cash used in financing activities for the ~~nine~~three months ended ~~June 30,~~December 31, 2022 primarily included repayment of funds from our ~~line~~lines of credit and ~~repayments~~repayment of term loans.

~~Table of Contents~~

Off-Balance Sheet Arrangements

As of ~~June 30,~~December 31, 2023, we had no off-balance sheet arrangements or obligations.

ITEM 4.

CONTROLS AND PROCEDURES

The Company maintains disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the specified time periods, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

Our management, with the participation of our Chief Executive Officer and our Principal Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of ~~June 30,~~December 31, 2023, the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our Chief Executive Officer and our Principal Financial Officer have concluded that as of ~~June 30,~~December 31, 2023, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

There has been no change in the ~~Company's~~Company’s overall internal control over financial reporting (as such is defined in Rules 13a-15(f) and 15(d)-15(f) under the Exchange Act) that occurred during the quarter ended ~~June 30,~~December 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

2924

Table of Contents

PART II - OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

Janel is occasionally subject to claims and lawsuits which typically arise in the normal course of business. While the outcome of these claims cannot be predicted with certainty, management does not believe that the outcome of any of these legal matters will have a material adverse effect on the Company’s business, results of operations, financial condition or cash flows.

ITEM 1A.

RISK FACTORS

For a discussion of the Company’s potential risks or uncertainties, please see “Part I—Item 1A—Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended September 30, ~~2022.~~2023. There have been no material changes to the risk factors disclosed in Part I—Item 1A of the Company’s ~~2022~~2023 Annual Report.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS ~~AND ISSUER PURCHASES OF EQUITY SECURITIES~~

There were no unregistered sales of equity securities during the ~~nine~~three months ended ~~June 30,~~December 31, 2023. In addition, there were no shares of Common Stock purchased by us during the ~~nine~~three months ended ~~June 30,~~December 31, 2023.

ITEM 5.

OTHER INFORMATION

Not applicable

ITEM 6.

EXHIBIT INDEX

~~10.1~~	Amended and Restated Credit Agreement, by and among Indco, Inc., Antibodies Incorporated, Aves Labs, Inc., Phosphosolutions LLC, Immunochemistry Technologies LLC, ECM Biosciences, LLC, Stephen Hall PhD LTD, Immunobioscience Corp., (collectively as borrowers), and each individually, a “Borrower”), and First Merchants Bank dated April 25, 2023 (filed herewith).
~~10.2~~	Fourth Amendment to Amended and Restated Loan and Security Agreement, by and among Santander Bank, N.A., as lender, and Janel Group, Inc., Expedited Logistics and Freight Services, LLC, and ELFS Brokerage, LLC (collectively as borrowers) and Janel Corporation and Expedited Logistics and Freight Services, LLC, as loan party obligors dated April 25, 2023 (filed herewith).
31.1	Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer (filed herewith)
31.2	Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer (filed herewith)
32.1	Section 1350 Certification of Principal Executive Officer (filed herewith)
32.2	Section 1350 Certification of Principal Financial Officer (filed herewith)
10.1	Amendment, dated December 1, 2023, to Membership Interest Purchase Agreement dated September 21, 2021, by and among Janel Group, Expedited Logistics and Freight Services, LLC and former shareholders of Expedited Logistics and Freight Services, LLC (filed herewith).
10.2	Sixth Amendment to Amended and Restated Loan and Security Agreement, dated December 21, 2023, by and among Santander Bank, N.A., as lender, and Janel Group, Inc., Expedited Logistics and Freight Services, LLC, and ELFS Brokerage, LLC, as borrowers, and Janel Corporation and Expedited Logistics and Freight Services, LLC, as loan party obligors (filed herewith).
101	Interactive data files providing financial information from the Company’s Quarterly Report on Form 10-Q for the quarter ended ~~June 30,~~December 31, 2023 for the three ~~and nine~~ months ended ~~June 30,~~December 31, 2023 and 2022 in Inline XBRL (eXtensible Business Reporting Language) pursuant to Rule 405 of Regulation S-T: (i) Condensed Consolidated Balance Sheets as of ~~June 30,~~December 31, 2023 and September 30, ~~2022,~~2023, (ii) Condensed Consolidated Statements of Operations for the three ~~and nine~~ months ended ~~June 30,~~December 31, 2023 and 2022, (iii) Condensed Consolidated Statement of Changes in Stockholders’ Equity for the three ~~and nine~~ months ~~June 30,~~December 31, 2023 and 2022, (iv) Condensed Consolidated Statements of Cash Flows for the ~~nine~~three months ended ~~June 30,~~December 31, 2023 and 2022, and (v) Notes to Condensed Consolidated Financial Statements.
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in the Interactive Data Files submitted as Exhibit 101) (filed herewith)

3025

Table of Contents

SIGNATURES~~SIGNATURES~~

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: ~~August 4, 2023~~February 2, 2024	JANEL CORPORATION
	Registrant

	/s/ Darren C. Seirer
	Darren C. Seirer
	Chairman, President and Chief Executive Officer
	(Principal Executive Officer)

Dated: ~~August 4,2023~~February 2, 2024	JANEL CORPORATION
	Registrant

	/s/ Vincent A. Verde
	Vincent A. Verde
	Principal Financial Officer, Treasurer and Secretary

			Page

Part I - Financial Information			3

	Item 1.	Financial Statements	3

		Condensed Consolidated Balance Sheets as of ~~June 30,~~December 31, 2023 (unaudited) and September 30, ~~2022~~2023	3

		Condensed Consolidated Statements of Operations for the three ~~and nine~~ months ended ~~June 30,~~December 31, 2023 and 2022 (unaudited)	4

		Condensed Consolidated Statement of Stockholders’ Equity for the three ~~and nine~~ months ended ~~June 30,~~December 31, 2023 and 2022 (unaudited)	5

		Condensed Consolidated Statements of Cash Flows for the ~~nine~~three months ended ~~June 30,~~December 31, 2023 and 2022 (unaudited)	6

		Notes to Condensed Consolidated Financial Statements (unaudited)	7

	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2017

	Item 4.	Controls and Procedures	29 24

Part II - Other Information			3025

	Item 1.	Legal Proceedings	3025

	Item 1A.	Risk Factors	3025

	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds ~~and Issuer Purchase of Equity Securities~~	3025

	Item 5.	Other Information	25

	Item 6.	Exhibit Index	3025

		Signatures	3126

Level 3		June 30, 2023				September 30, 2022
Contingent earnout liabilities		$	3,187			$	4,580